Kaival Brands Innovations (KAVL) 10-K13 Feb 242023 FY Annual reportFinancial data

Company Profile

Cover

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Oct. 31, 2023	Feb. 13, 2024	Apr. 28, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Oct. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--10-31
Entity File Number	001-04641
Entity Registrant Name	Kaival Brands Innovations Group, Inc.
Entity Central Index Key	0001762239
Entity Tax Identification Number	83-3492907
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	4460 Old Dixie Highway
Entity Address, City or Town	Grant-Valkaria
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32949
City Area Code	(833)
Local Phone Number	452-4825
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	KAVL
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 33,701,454
Entity Common Stock, Shares Outstanding		2,846,335
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	206
Auditor Name	MaloneBailey, LLP
Auditor Location	Houston, Texas

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Oct. 31, 2023	Oct. 31, 2022
CURRENT ASSETS:
Cash	$ 533,659	$ 3,685,893
Accounts receivable	1,869,276	574,606
Other receivable - related party - short term	0	1,539,486
Inventories, net	4,071,824	1,239,725
Prepaid expenses	430,668	426,407
Income tax receivable	0	1,607,302
Total current assets	6,905,427	9,073,419
Fixed assets, net	2,842	0
Intangible assets, net	11,468,309	0
Other receivable - related party - net of current portion	0	2,164,646
Right of use asset - operating lease	1,008,428	1,198,969
TOTAL ASSETS	19,385,006	12,437,034
CURRENT LIABILITIES:
Accounts payable	374,332	40,023
Accounts payable - related party	2,474,817	0
Loans payable, net	799,471	0
Accrued expenses	736,194	1,099,157
Customer deposits	0	44,973
Customer refund due	392,406	0
Deferred revenue	0	235,274
Operating lease obligation - short term	184,568	166,051
Total current liabilities	4,961,788	1,585,478
LONG TERM LIABILITIES:
Operating lease obligation, net of current portion	866,207	1,050,776
TOTAL LIABILITIES	5,827,995	2,636,254
STOCKHOLDERS’ EQUITY:
Common stock ($0.001 par value, 1,000,000,000 shares authorized, 2,793,529 and 2,674,718 shares issued and outstanding as of October 31, 2023 and October 31, 2022, respectively)	2,793	2,675
Additional paid-in capital	44,317,266	29,429,281
Accumulated deficit	(30,763,948)	(19,631,176)
Total Stockholders’ Equity	13,557,011	9,800,780
TOTAL LIABILITIES & EQUITY	19,385,006	12,437,034
Series A Preferred Stock [Member]
STOCKHOLDERS’ EQUITY:
Preferred Stock, Value, Issued	0	0
Series B Preferred Stock [Member]
STOCKHOLDERS’ EQUITY:
Preferred Stock, Value, Issued	$ 900	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Oct. 31, 2023	Oct. 31, 2022
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	2,793,386	2,674,718
Common stock, shares outstanding	2,793,386	2,674,718
Series A Preferred Stock [Member]
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Preferred Stock [Member]
Preferred stock, shares authorized	900,000	900,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	900,000	0
Preferred stock, shares outstanding	900,000	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Oct. 31, 2023	Oct. 31, 2022
Revenues
Revenues, net	$ 12,395,134	$ 12,701,539
Revenues - related party	10,828	68,139
Royalty revenue	780,929	117,292
Excise tax on products	(99,873)	(125,513)
Total revenues, net	13,087,018	12,761,457
Cost of revenues
Cost of revenue - related party	10,512,423	11,345,912
Cost of revenue - other	0	174,520
Total cost of revenue	10,512,423	11,520,432
Gross profit	2,574,595	1,241,025
Operating expenses
Advertising and promotion	2,450,721	2,679,308
General and administrative expenses	10,787,775	12,950,373
Total operating expenses	13,238,496	15,629,681
Other income (expense)
Interest expense, net	(466,523)	4
Total other income (expense)	(466,523)	4
Loss before income taxes provision	(11,130,424)	(14,388,652)
Provision for (benefit from) income taxes	2,348	(18,317)
Net loss	(11,132,772)	(14,370,335)
Preferred stock dividend	(112,500)	0
Net loss attributable to common shareholders	$ (11,245,272)	$ (14,370,335)

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) - $ / shares	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Income Statement [Abstract]
Net loss per common share basic	$ (4.13)	$ (7.60)
Net loss per common share diluted	$ (4.13)	$ (7.60)
Weighted average number of common shares outstanding, basic	2,721,080	1,890,971
Weighted average number of common shares outstanding, diluted	2,721,080	1,890,971

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Series A Preferred Stocks [Member]	Series B Preferred Stocks [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Oct. 31, 2021	$ 3,000		$ 1,438	$ 21,580,716	$ (5,260,841)	$ 16,324,313
Beginning balance, shares at Oct. 31, 2021	3,000,000		1,437,869
Stock Issued for Services - RSUs			$ 6	172,373		172,379
Stock issued for services - RSUs, (in shares)			5,870
Common shares settled and cancelled			$ (2)	(59,860)		(59,862)
Common shares settled and cancelled (in shares)			(2,130)
Common stock issued for compensation			$ 2	65,321		65,323
Common stock issued for compensation, shares			1,888
Exercise of common stock warrants			$ 41	1,625,609		1,625,650
Exercise of common stock warrants, shares			40,744
Converted Series A Convertible Preferred Stock	$ (3,000)		$ 1,190	1,810
Converted Series A Convertible Preferred Stock, shares	(3,000,000)		1,190,477
Stock option expense				6,043,312		6,043,312
Net loss					(14,370,335)	(14,370,335)
Ending balance, value at Oct. 31, 2022			$ 2,675	29,429,281	(19,631,176)	9,800,780
Ending balance, shares at Oct. 31, 2022			2,674,718
Common shares issued for purchase of intangible assets			$ 95	1,119,705		1,119,800
Common shares issued for purchase of intangible assets, shares			95,239
Preferred series B shares issued for purchase of intangible assets		$ 900		9,047,080		9,047,980
Preferred series B shares issued for purchase of intangible assets, shares		900,000
Stock warrants issued for purchase of intangible assets				1,264,396		1,264,396
Common shares issued for services			$ 4	51,506		51,510
Common shares issued for services, shares			4,381
Common shares issued for loan			$ 19	130,459		130,478
Common shares issued for Loan, shares			19,048
Stock option expense				3,168,430		3,168,430
Stock warrant expense				218,909		218,909
Preferred stock dividend				(112,500)		(112,500)
Net loss					(11,132,772)	(11,132,772)
Ending balance, value at Oct. 31, 2023		$ 900	$ 2,793	$ 44,317,266	$ (30,763,948)	$ 13,557,011
Ending balance, shares at Oct. 31, 2023		900,000	2,793,386

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Oct. 31, 2023	Oct. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (11,132,772)	$ (14,370,335)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	0	237,702
Stock options expense	3,168,430	6,043,312
Stock warrants expense	218,909	0
Depreciation and amortization	328,304	0
Amortization of debt discount	463,160	0
Bad debt expense	47,727	0
ROU operating lease expense	190,541	132,890
Inventory reserve	381,512	0
Write-off of inventory	105,057	259,563
Changes in current assets and liabilities:
Accounts receivable	(1,342,397)	1,410,580
Other receivable - related party	3,704,132	(3,704,132)
Prepaid expenses	325,739	(106,876)
Inventory	(3,318,668)	13,827,082
Inventory deposit - related party	0	2,925,000
Income tax receivable	1,607,302	146,292
Accounts payable	334,309	(202,806)
Accounts payable - related party	2,474,817	(12,667,769)
Accrued expenses	(475,463)	519,553
Deferred revenue	(235,274)	235,274
Customer deposits	(44,973)	44,973
Customer refunds due	392,406	(316,800)
Right of use liabilities - operating lease	(166,052)	(118,633)
Net cash used in operating activities	(2,973,254)	(5,705,130)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid for equipment	(3,480)
Transaction acquisition costs	(312,289)	0
Net cash used in investing activities	(315,769)	0
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from the exercise of warrants	0	1,625,650
Settled RSU shares with cash		(59,862)
Proceeds from loans payable	1,272,980	0
Payments on loans payable	(1,136,191)	0
Net cash provided by financing activities	136,789	1,565,788
Net change in cash	(3,152,234)	(4,139,342)
Beginning cash balance	3,685,893	7,825,235
Ending cash balance	533,659	3,685,893
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest paid	3,363	0
Income taxes paid	0	0
NON-CASH TRANSACTIONS
Common shares issued for acquisition of intangible assets	1,119,800	0
Common shares issued for services-transaction cost	51,510	0
Series B preferred stock shares issued for acquisition of intangible assets	9,047,980	0
Stock warrants issued for acquisition of intangible assets	1,264,396	0
Preferred stock dividend	112,500	0
Insurance financed by third party	330,000
Common stock issued for note payable financing	130,478
Conversion of Series A Preferred Stock Shares to Common Stock Shares	0	25,000
New ROU leased asset recognized	$ 0	$ 1,276,255

Organization and Description of

Organization and Description of Business	12 Months Ended
Organization and Description of Business	Oct. 31, 2023
Accounting Policies [Abstract]
Organization and Description of Business	Note 1 – Organization and Description of Business Kaival Brands Innovations Group, Inc. (the “Company,” the “Registrant,” “we,” “us,” or “our”), formerly known as Quick Start Holdings, Inc., was incorporated on September 4, 2018, in the State of Delaware. Current Description of Business The Company is focused on growing and incubating innovative and profitable products into mature, dominant brands. On March 9, 2020, the Company entered into an exclusive distribution agreement (the “Distribution Agreement”) of certain electronic nicotine delivery systems (“ENDS”) and related components (the “Products”) with Bidi Vapor, LLC, a Florida limited liability company (“Bidi”), a related party company that is also owned by Nirajkumar Patel, the Chief Science and Regulatory Officer and director of the Company. The Distribution Agreement was amended and restated on May 21, 2020, again on April 20, 2021, again on June 10, 2022 , On August 31, 2020, the Company formed Kaival Labs, Inc., a Delaware corporation (herein referred to as “Kaival Labs”), as a wholly owned subsidiary of the Company, for the purpose of developing Company-branded and white-label products and services. The Company has not yet launched any Kaival-branded product, nor has it begun to provide white label wholesale solutions for other product manufacturers. On March 11, 2022, the Company formed Kaival Brands International, LLC, a Delaware limited liability company (herein referred to as “KBI”), as a wholly owned subsidiary of the Company, for the purpose of entering into an international licensing agreement with Philip Morris Products S.A. (“PMPSA”), a wholly owned affiliate of Philip Morris International Inc. (“PMI”). On June 13, 2022, the Company’s wholly owned subsidiary, KBI, entered into the PMI License Agreement with PMPSA, a wholly owned affiliate of PMI, for the development and distribution of ENDS products in certain markets outside of the United States, subject to market (or regulatory) assessment. The PMI License Agreement grants to PMPSA a license of certain intellectual property rights relating to Bidi’s ENDS device, known as the BIDI® Stick in the United States, as well as potentially newly developed devices, to permit PMPSA to manufacture, promote, sell, and distribute such ENDS device and newly developed devices, in international markets, outside of the United States. Current Product Offerings Pursuant to the A&R Distribution Agreement, The Company sells and resells electronic nicotine delivery systems, which it may refer to herein as “ENDS Products”, or “e-cigarettes”, to non-retail level customers. The sole Product the Company resells is the “BIDI ® ® COVID-19 In January 2020, the World Health Organization (the “WHO”) announced a global health emergency because of a new strain of coronavirus (“COVID-19”) originating in Wuhan, China and the risks to the international community as the virus spread globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic based on the rapid increase in global exposure. The Company was indirectly impacted by supply chain issues and regulatory oversight. The Company believes that many retailers and distributers relaxed their compliance standards as an indirect result of COVID-19 for two reasons: (i) government enforcement of regulations was very limited due to imposed social restrictions, resulting in less in-person monitor enforcement by government officials and (ii) retail stores experienced light foot traffic from customers due to COVID-19 restrictions and fears, which resulted in relaxed compliance in an effort to generate additional revenue. Impact of FDA PMTA Determinations and August 2022 11 th In September 2021, in connection with the PMTA process, the FDA effectively “banned” flavored ENDS by denying nearly all then-pending PMTAs for such products. Following the issuance of Marketing Denial Orders (“MDO”), manufacturers are required to stop selling non-tobacco flavored ENDS products. Bidi, along with nearly every other company in the ENDS industry, received a MDO for its non-tobacco flavored ENDS products. With respect to Bidi, the MDO covered all non-tobacco flavored BIDI® Sticks, including its Arctic (menthol) BIDI® Stick. As a result, beginning in September 2021, Bidi challenged the MDO. First, on September 21, 2021, separate from the judicial appeal of the MDO in its entirety, Bidi filed a 21 C.F.R. §10.75 internal the FDA review request specifically of the decision to include the Arctic (menthol) BIDI® Stick in the MDO. In May 2022, the FDA issued a determination that it views the Arctic BIDI® Stick as a flavored ENDS product, and not strictly a menthol flavored product. On September 29, 2021, Bidi petitioned the U.S. Court of Appeals for the Eleventh Circuit (the “11 th On October 14, 2021, Bidi requested that the FDA re-review the MDO and reconsider its position that Bidi did not include certain scientific data in its applications sufficient to allow the PMTAs to proceed to scientific review. In light of this request, on October 22, 2021, pursuant to 21 C.F.R. § 10.35(a), the FDA issued an administrative stay of Bidi’s MDO pending its re-review. Subsequently, the FDA decided not to rescind the MDO and lifted its administrative stay on December 17, 2021. Following the lifting of the FDA’s administrative stay, Bidi filed a renewed motion to stay the MDO with the 11th Circuit. On February 1, 2022, the appellate court granted Bidi’s motion to stay (i.e., put on hold) the MDO, pending the litigation on the merits. Oral arguments in the merits-based proceeding were held on May 17, 2022. On August 23, 2022, the U.S. Court of Appeals for the Eleventh Circuit set aside the MDO issued to the non-tobacco flavored BIDI® Sticks and remanded Bidi’s Premarket Tobacco Product Application (“PMTA”) back to the FDA for further review. Specifically, the Court held that the MDO was “arbitrary and capricious” in violation of the Administrative Procedure Act (“APA”) because the FDA failed to consider the relevant evidence before it, specifically Bidi’s aggressive and comprehensive marketing and sales-access-restrictions plans designed to prevent youth appeal and access. The opinion further indicated that the FDA did not properly review the data and evidence that it has long made clear are critical to the appropriate for the protection of the public health (“APPH”) standard for PMTAs set forth in the Tobacco Control Act including, in Bidi’s case, “product information, scientific safety testing, literature reviews, consumer insight surveys, and details about the company’s youth access prevention measures, distribution channels, and adult-focused marketing practices,” which “target only existing adult vapor product users, including current adult smokers,” as well as the Company’s retailer monitoring program and state-of-the-art anti-counterfeit authentication system. Because a MDO must be based on a consideration of the relevant factors, such as the marketing and sales-access-restrictions plans, the denial order was deemed arbitrary and capricious, and vacated by the FDA. The FDA did not appeal the 11th Circuit’s decision. The Agency had until October 7, 2022 (45 days from the August 23, 2022 decision) to either request a panel rehearing or a rehearing “en banc” (a review by the entire 11 th In the meantime, the Company anticipates continued ability to market and sell the non-tobacco flavored BIDI® Sticks, subject to the FDA’s enforcement discretion, for the duration of the PMTA scientific review. Separately, on or about May 13, 2022, the FDA placed the tobacco-flavored Classic BIDI® Stick into the final Phase III scientific review. In March 2023, FDA issued a deficiency letter regarding the Classic BIDI® Stick PMTA, to which Bidi submitted in June 2023. Subsequently, on January 22, 2024, FDA issued a MDO for the Classic BIDI® Stick. On January 26, 2024, Bidi filed a petition for review of the MDO with the 11 th Risks and Uncertainties The FDA has indicated that it is prioritizing enforcement of unauthorized ENDS against companies (1) that never submitted PMTAs, (2) whose PMTAs have been refused acceptance or filing by the FDA, (3) whose PMTAs remain subject to MDOs, and (4) that are continuing to market unauthorized synthetic nicotine products after the July 13, 2022, cutoff. Subject to FDA’s enforcement discretion, until the scientific review process is complete on each of Bidi’s PMTA’s, the Company views the risk of FDA enforcement against Bidi as low. The Company anticipates FDA will move forward with a review of Bidi’s PMTA on remand, as directed by the Court; however, the Company cannot provide any assurances as to the timing or outcome.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	12 Months Ended
Basis of Presentation and Significant Accounting Policies	Oct. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Note 2 – Basis of Presentation and Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the financial statements of the Company’s wholly-owned subsidiaries, Kaival Labs and Kaival Brands International. Intercompany transactions are eliminated. Basis of Presentation This summary of significant accounting policies is presented to assist in understanding the Company’s consolidated financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America (“GAAP”) and have been consistently applied in the preparation of the consolidated financial statements. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates. Cash The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. There were no The Federal Deposit Insurance Corporation (“FDIC”) insures deposits according to the ownership category in which the funds are insured and how the accounts are titled. The standard deposit insurance coverage limit is $ 250,000 252,586 2,912,793 Advertising and Promotion All advertising, promotion and marketing expenses, including commissions, are expensed when incurred. Accounts Receivable and Allowance for Doubtful Accounts Receivables are stated at cost, net of an allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts based on the management’s assessment of the collectability of accounts receivable. A considerable amount of judgment is required in assessing the amount of the allowance and the Company considers the historical level of credit losses and collection history and applies percentages to aged receivable categories. The Company makes judgments about the creditworthiness of debtors based on ongoing credit evaluations and monitors current economic trends that might impact the level of credit losses in the future. If the financial condition of the debtors were to deteriorate, resulting in their inability to make payments, a larger allowance may be required. As of October 31, 2023, based upon management’s assessment of the accounts receivable aging and the customers’ payment history, the Company has determined that no allowance for doubtful accounts is required. The Company also had no On January 22, 2024, the FDA issued an MDO on Bidi Vapor’s “Classic” BIDI ® Stick PMTA. The Company evaluated the impact of this MDO to the financial statements and recorded an estimated accrual for potential customer returns of the “Classic” products of $ 113,243 Inventories All product inventory is purchased from a related party, Bidi. Inventories are stated at the lower of cost and net realizable value. Cost includes all costs of purchase and other costs incurred in bringing the inventories to their present location and condition. The Company determines cost based on the first-in, first-out (“FIFO”) method. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. As of October 31, 2023, the inventories only consisted of finished goods and were located in three locations; the Kaival main warehouse and two customer warehouses whose service agreements are on a consignment basis with Kaival. During fiscal year 2023, the Company had a write-off of $ 105,057 no On January 22, 2024, the FDA issued an MDO on Bidi Vapor’s “Classic” BIDI ® Stick PMTA. The Company evaluated the impact of this MDO to the financial statements and recognized a full reserve for all remaining “Classic” products on hand amounting to $381,512 as of October 31, 2023 in order to comply with ASC 855 Subsequent Events. See Note 12. Revenue Recognition The Company adopted ASC 606, Revenue from Contracts with Customers Deferred Revenue The Company accepts partial payments for orders from wholesale customers, which it holds as deposits or deferred revenue, until the Company has received full payment and orders are shipped to the customer. Revenue for these orders is recognized at the time of shipment to the customer. As of October 31, 2023, and October 31, 2022, the Company has $ 0 44,973 0 235,274 Customer Refunds In the normal course of business, the Company issues credits for product returns and certain customer incentives related to rebates, discounts and promotions. When such credits exceed amounts receivable from customers, the Company recognizes such excess amounts as customer refunds which will be applied against future product purchases. As of October 31, 2023, and October 31, 2022, the Company had $ 392,406 0 Products Revenue The Company generates products revenue from the sale of the Products (as defined above) to non-retail customers. The Company recognizes revenue at a point in time based on management’s evaluation of when performance obligations under the terms of a contract with the customer are satisfied and control of the Products has been transferred to the customer. In most situations, transfer of control is considered complete when the products have been shipped to the customer. The Company determined that a customer obtains control of the Product upon shipment when title of such product and risk of loss transfer to the customer. The Company’s shipping and handling costs are fulfillment costs, and such amounts are classified as part of cost of sales. The Company offers credit sales arrangements to non-retail (or wholesale) customers and monitors the collectability of each credit sale routinely. Revenue is measured by the transaction price, which is defined as the amount of consideration expected to be received in exchange for providing goods to customers. The transaction price is adjusted for estimates of known or expected variable consideration, which includes refunds and returns as well as incentive offers and promotional discounts on current orders. Estimates for sales returns are based on, among other things, an assessment of historical trends, information from customers, and anticipated returns related to current sales activity. These estimates are established in the period of sale and reduce revenue in the period of the sale. Variable consideration related to incentive offers and promotional programs are recorded as a reduction to revenue based on amounts the Company expects to collect. Estimates are regularly updated, and the impact of any adjustments are recognized in the period the adjustments are identified. In many cases, key sales terms such as pricing and quantities ordered are established at the time an order is placed and incentives have very short-term durations. Amounts billed and due from customers are short term in nature and are classified as receivable since payments are unconditional and only the passage of time related to credit terms is required before payments are due. The Company does not grant payment financing terms greater than one year. Payments received in advance of revenue recognition are recorded as deferred revenue, as noted above. Royalty Revenue On June 13, 2022, KBI entered into the PMI License Agreement with PMPSA, effective as of May 13, 2022 (the “PMI Commencement Date”). Pursuant to the PMI License Agreement, KBI granted PMPSA an exclusive irrevocable license to use its technology, documentation, and intellectual property to make, distribute, and sell disposable nicotine e-cigarettes Products based on the intellectual property in certain international markets set forth in the PMI License Agreement (the “PMI Markets”). The Company has the exclusive international distribution rights to the Products and, in order to allow KBI to fulfill its obligations set forth in the PMI License Agreement, has contributed the international distribution rights for the PMI Markets to KBI as set forth in a Capital Contribution Agreement, dated June 10, 2022. The sublicense granted to PMPSA is exclusive in the PMI Markets and neither KBI nor any of its affiliates can sell, promote, use, or distribute any competing products in the PMI Markets for the duration of the term of the PMI License Agreement and any Sell-Out Period (as defined in the PMI License Agreement). PMSPA will be responsible for any regulatory filings necessary to sell the Products in the PMI Markets. Both KBI and PMPSA agree to work together in the registration and maintenance of the Intellectual Property, but KBI will bear all cost and expense to implement the registration strategy. Finally, PMPSA has agreed to potential future development services with KBI in the PMI Markets and has been granted certain rights with respect to potential future products. The initial term of the PMI License Agreement is five (5) years and automatically renews for an additional five-year period unless PMPSA has failed to meet the agreed upon minimum key performance indicators set forth in the PMI License Agreement, in which case the PMI License Agreement will automatically terminate at the end of the initial license term. In consideration for the grant of the licensed rights, PMPSA agreed to pay to KBI a royalty equal to a percentage of the base price of the first sale of each unit of Product manufactured. In addition, before the launch of the first product in a market and each anniversary of such launch, PMPSA agrees to pre-pay to KBI a guaranteed minimum royalty based on the estimated royalties payable by PMPSA to KBI in relation to all markets in the twelve (12)-month period following the first launch or each successive anniversary of the first launch, subject to an aggregate maximum guaranteed royalty payment for all markets for each applicable twelve (12)-month period. PMPSA may require modification of certain products to be sold under the PMI Licensing Agreement to be modified for a PMI Market. Pursuant to the PMI Licensing Agreement, PMPSA has absolute discretion over sales, marketing, product branding and packaging pertaining to sales in the PMI Markets, as well as the right to select the specific PMI Markets in which to launch commercialization and determine what product types are to be promoted in each market, subject to sales and marketing plans and annual business plans set by PMPSA and certain expansion criteria agreed between PMPSA and KBI. Royalty revenue earned from the PMI License Agreement is recognized in the period the sales of the Product manufactured occurs. As of October 31, 2023, amounts receivable from PMPSA in connection with the PMI License Agreement totaled $ 1,002,196 289,672 712,524 The PMI License Agreement contains customary representations, warranties, covenants, and indemnification provisions; however, KBI’s liability under the PMI License Agreement is capped at the greater of: (i) Ten Million Dollars ($ 10,000,000 30,000,000 On June 10, 2022, Bidi entered into a License Agreement (the “KBI License Agreement”) with KBI, pursuant to which KBI has the exclusive irrevocable license to use Bidi’s licensed intellectual property to the extent necessary for KBI to fulfill its obligations set forth in the PMI Licensing Agreement. Such irrevocable license includes: (i) the right of KBI to grant sub-licenses to PMPSA under the PMI License Agreement for the express purposes set forth in the PMI License Agreement, but for no other purpose; (ii) the right of KBI to grant to PMPSA the right to grant sub-sub-licenses in the manner set forth in the PMI License Agreement, but for no other purpose; and (iii) certain branding rights to the extent (but only to the extent) necessary to permit KBI to perform its obligations to PMPSA as set forth in the PMI License Agreement. On August 12, 2023, the Company executed and entered into a Deed of Amendment No. 1 (the “PMI License Amendment”) with PMPSA, Bidi and KBI. Pursuant to the PMI License Amendment (which has an effective date of June 30, 2023), the following material changes have been made to the PMI License Agreement: 1. Royalty Rate. The royalty paid by PMPSA to KBI will no longer be based on sales price of the Product being sold, but rather on the volume of liquid contained within Product being sold. The royalty will be on a sliding scale of between $0.08 to $0.16 per sale based on the volume of liquid contained in the Product, increasing to between $0.10 to $0.20 per sale upon meeting certain sales milestones. 2. Elimination of Certain Potential Royalty Adjustments. Certain potential adjustments to the royalties receivable by KBI as provided for in the PMI License Agreement have been eliminated. 3. Guaranteed Royalty. The guaranteed royalty payment owed to KBI under the PMI License Agreement has been eliminated. Instead, royalties will be paid on a quarterly basis going-forward based on actual sales. Any unpaid guaranteed royalty has been cancelled. 4. Insurance Tail Requirements. KBI’s requirement to keep certain tail insurance after the expiration or termination of the PMI Licensing Agreement was reduced from 6 years to 2 years. 5. Markets. The identification of the PMI Markets that PMI may enter has been expanded to cover certain additional territories. 6. Net Reconciliation Payment to KBI. As a result of the changes to the PMI License Agreement described in paragraphs 1 thought 3 above, the value of such changes was calculated and reconciled as of the date of commencement of the PMI Licensing Agreement through June 30, 2023. On September 8, 2023, the Company received the Net Reconciliation Payment from PMPSA of $ 134,981 The KBI License Agreement provides that KBI shall pay Bidi license fees equivalent to 50% of the adjusted earned royalty payments, after any offsets due to jointly agreed costs such development costs incurred for entry to specific international markets. During the year ended October 31, 2023, the Company paid license fees of approximately $150,000 to Bidi. As of October 31, 2023 and 2022, no additional license fees are owed to Bidi. Concentration of Revenues and Accounts Receivable For the fiscal year 2023, (i) approximately 15% or $ 1,986,970 1,842,511 1,817,310 1,759,563 1,501,439 For the fiscal year 2022, (i) approximately 30% or $ 3,945,534 ® 1,892,245 1,472,888 FAVS Business LLC with an outstanding balance of $ 302,400 300,590 164,987 Favs Business with an outstanding balance of $ 375,425 85,510 Share-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments (share-based payments, referred to herein as “SBP”) based on the grant-date fair value of the award. That cost is recognized over the period during which a recipient is required to provide service in exchange for the SBP award—the requisite service period (vesting period). For SBP awards subject to performance conditions, compensation is not recognized until the performance condition is probable of occurrence. The grant-date fair value of share options is estimated using the Black-Scholes-Merton option-pricing model based on certain assumptions which include the expected term, expected volatility and discount rate. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The expected volatility is based on the volatility in the trading of the Common Stock over the expected term of the award. The assumed discount rate is the default risk-free ten-year interest rate for U.S. Treasury bills. Net Loss Per Share Basic net income (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period, without consideration of potential common stock equivalents. Diluted net income (loss) per share is calculated by dividing net income (loss) available to common stockholders by the weighted average number of common stock outstanding plus common share equivalents from conversion of dilutive stock options and warrants using the treasury method and preferred stock using the as-converted method, except when antidilutive. In the event of a net loss, the effects of all potentially dilutive shares are excluded from the diluted net loss per share calculation as their inclusion would be antidilutive. For the year ended October 31, 2023 the outstanding common stock equivalents excluded from the computation of diluted net loss were 449,106 242,548 357,120 152,489 110,396 Income Tax Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes related primarily to differences between the recorded book basis and the tax basis of assets and liabilities for financial and income tax reporting. Deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes are also recognized for operating losses that are available to offset future taxable income and tax credits that are available to offset future federal income taxes. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material adverse effect on the Company’s financial condition, results of operations, or cash flow. The Company has Federal net operating loss (“NOL”) carryforwards, consisting of total deferred tax assets, totaling approximately $ 23.8 0.2 7,319,289 4,286,289 Fair Value of Financial Instruments The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. ASC 820, Fair Value Measurements and Disclosures ● Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. ● Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. ● Level 3 – Inputs that are both significant to the fair value measurement and unobservable. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of October 31, 2023 and 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, restricted cash, accounts receivable, accounts payable and accrued expenses. As of October 31, 2023, and 2022, the Company did not have any financial assets or liabilities measured and recorded at fair value on a recurring basis. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplified the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplified the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that required entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revised the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revised the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (“EPS”) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. ASU 2020-06 was effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption was permitted. The Company has elected to early adopt ASU 2020-06 effective beginning November 1, 2022. There was no impact on the consolidated financial statements as a result of adopting this standard. The Company does not believe that any recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements. However, In March 2022, the FASB issued ASU 2022-02, “Financial Instruments-Credit Losses (Topic 326), Troubled Debt Restructurings and Vintage Disclosures.” ASU 2022-02 addresses areas identified by the FASB as part of its post-implementation review of the credit losses standard (ASU 2016-13) that introduced the current expected credit loss (“CECL”) model. The amendments eliminate the accounting guidance for troubled debt restructurings (“TDRs”) by creditors that have adopted the CECL model and enhance the disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty. In addition, the amendments require a public business entity to disclose current-period gross write-offs for financing receivables and net investment in leases by year of origination in the vintage disclosures. The amendments in this ASU should be applied prospectively, except for the transition method related to the recognition and measurement of TDRs, where an entity has the option to apply a modified retrospective transition method resulting in a cumulative-effect adjustment to retained earnings in the period of adoption. This is not effective for the Company until November 1, 2023

Going Concern

Going Concern	12 Months Ended
Going Concern	Oct. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 3 – Going Concern The accompanying financial statements of the Company are prepared in accordance with U.S. GAAP applicable to a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board (“FASB”), Accounting Standards Update (“ASU”) No. 2014-15, Presentation of Financial Statements – Going Concern The Company will need significant additional funds to satisfy its outstanding payables, fund its working capital, and fully implement its business plan as the Company seeks to grow its revenues and ultimately achieve positive cash flow and profitability. In addition, the Company’s ability to continue as a going concern is adversely affected by the uncertainty surrounding Bidi’s PMTA process with FDA and outcome of Bidi’s petition with the 11th Circuit Court of Appeals regarding the FDA’s January 2024 MDO relating to Classic Bidi ® Management plans to continue similar operations with increased marketing and enhanced efforts to increase sales, which the Company believes will result in increased revenue and ultimately net income and positive cash flow from operations. However, there is no assurance that the Company’s plans will be able to generate expected or greater amounts of revenues or ever achieve profitability due to the factors listed above as well as the regulation and public perception of ENDS products and the various other risks faced by the Company. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of these or other risks or uncertainties.

Acquisition of GoFire Assets

Acquisition of GoFire Assets	12 Months Ended
Acquisition of GoFire Assets	Oct. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisition of GoFire Assets	Note 4 – Acquisition of GoFire Assets On May 30, 2023 (the “Closing Date”), the Company and Kaival Labs entered into an Asset Purchase Agreement (the “GoFire APA”) with GoFire, Inc. (“GoFire”) to purchase certain intellectual property assets of GoFire consisting of various patents concerning electronic vaporizers and related technologies (the “Purchased Assets”) in exchange for equity securities of the Company and certain contingent cash consideration. The Company participated in this transaction with the intent to diversify its product offerings and create both near and long-term revenue opportunities. The Purchased Assets consist of 19 existing and 47 pending patents with novel technologies related to vaporization and inhalation. Pursuant to the terms of the GoFire APA, the Company paid to GoFire, in addition to certain contingent cash consideration described below, consideration in the form of equity securities of the Company consisting of (i) an aggregate of 95,239 900,000 0.001 95,239 The Company has determined that the acquisition of the Purchased Assets constitutes an asset acquisition and has recorded the assets under a cost accumulation model. Assets acquired and liabilities assumed are recognized at cost, which is the consideration the acquirer transferred to the seller, as well as direct transaction costs, on the acquisition date. The cost of the acquisition is then allocated to the assets acquired based on their relative fair values. The cost of acquisition does not include any contingent consideration related to contingent cash payments as those obligations are contingent in future amount of royalties and will be recognized when the contingency is resolved, and the consideration is paid or becomes payable. Goodwill is not recognized in asset acquisition. The Purchased Assets have been recorded at a cost of $11,795,975 and are included in Intangible Assets in the consolidated balance sheet. The consideration paid for the GoFire APA was as follows (see Note 5): Schedule of consideration paid Common Stock $ 1,119,800 Series B Preferred Stock 9,047,980 Common Stock Warrants 1,059,523 Transaction Costs 568,672 Total consideration $ 11,795,975 The fair value of the Common Stock is based on the publicly traded share price as of the acquisition date and represents a Level 1 measurement. The fair value of the Series B Preferred Stock and Common Stock Warrants were determined using the Black-Scholes Option Pricing model. The fair value measurements are based on significant unobservable inputs, including management estimates and assumptions, and thus represent Level 3 measurements.

Intangible Assets, net

Intangible Assets, net	12 Months Ended
Intangible Assets, net	Oct. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Note 5 – Intangible Assets, net The Company’s intangible assets include patents and technology that were acquired pursuant to the GoFire APA. The cost and accumulated amortization of the intangible assets amounted to $ 11,795,975 327,666 15 14.6 The Company recognized an amortization expense of $327,666 for the year ended October 31, 2023. Amortization expense is included under general and administrative expenses in the consolidated statement of operations. Future amortization expense of intangible assets is as follows: Schedule of future amortization expense of intangible assets 2024 $ 786,398 2025 786,398 2026 786,398 2027 786,398 2028 786,398 Thereafter 7,536,319 Total $ 11,468,309

Loans Payable

Loans Payable	12 Months Ended
Loans Payable	Oct. 31, 2023
Debt Disclosure [Abstract]
Loans Payable	Note 6 – Loans Payable On May 9, 2023, the Company entered into two loan agreements which are collateralized by all assets of the Company until the loans are repaid in full. As illustrated in the following table, under the terms of these agreements, the Company received the disclosed Purchase Price and agreed to repay the disclosed Purchase Amount, which is collected by the lenders at the disclosed weekly payment rate. The Company’s former Chief Executive Officer, Eric Mosser personally guarantees the performance of these loans. The Company has accounted for these agreements as loans under ASC 860 because while we provided rights to current and future receipts, we still had control over the receipts. The difference between the Purchase Amount and the Purchase Price is imputed interest that is recorded as interest expense when paid. The following table shows our loan agreements as of October 31, 2023, and there were none as of October 31, 2022: Schedule of loan agreements Purchase Payment Payment Deferred Inception Date Price Purchased Amount Outstanding Balance frequency Rate Finance Fees May 9, 2023 $ 400,000 $ 580,000 $ 53,709 Weekly 20,714 $ 3,434 May 9, 2023 400,000 580,000 80,467 Weekly 20,714 5,247 $ 800,000 $ 1,160,000 $ 134,176 $ 8,681 On August 9, 2023, the Company entered into a Securities Purchase Agreement (the “SPA”) with AJB Capital Investments, LLC (“AJB”), pursuant to which the Company sold a Promissory Note in the principal amount of $650,000 (the “Note”) to AJB in a private transaction for a purchase price of $585,000 (giving effect to original issue discount of $65,000). The Note matures on February 8, 2024 (the “Maturity Date”) and bears interest at the rate of 10% per annum. Interest shall be payable on a monthly basis beginning on the date that is one month following the date of issuance of the Note. Provided no event of default (as defined in the Note) is in effect as of the Maturity Date, the Company may elect to extend the Maturity Date for a period of six (6) months. Pursuant to the terms of the SPA, the Company paid a commitment fee to AJB in the form of 19,048 shares of Common Stock (the “Commitment Fee Shares”) with a relative fair value of $130,478 which was recognized as discount to the note. The debt discount and issuance costs are amortized over the term of the note. Amortization expense amounted to $122,273 for the year ended October 31, 2023. Under the SPA, the Company has the right to repurchase half of the Commitment Fee Shares if the Note is repaid in full prior to maturity . As of October 31, 2023 the carrying value of the loan and unamortized debt discount and issuance costs were $513,295 and $136,705 respectively On May 20, 2023, the Company obtained a nine month loan from Westfield Bank to finance the annual D&O insurance. The principal amount was $ 342,001 7.79 152,000

Leases

Leases	12 Months Ended
Leases	Oct. 31, 2023
Leases
Leases	Note 7 – Leases The Company capitalizes all leased assets pursuant to ASU 2016-02, Leases (Topic 842) (“Topic 842”), which requires lessees to recognize right-of-use (“ROU”) assets and lease liability, initially measured at present value of the lease payments, on its balance sheet for leases with terms longer than 12 months and classified as either financing or operating leases. The Company excludes short-term leases having initial terms of 12 months or less from Topic 842 as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term. The Company does not have financing leases and only one operating lease for office space and inventory storage space with a related party, as of October 31, 2023. Certain of the Company’s leases, have and may in the future, include renewal options, which have been and might be in the future, included in the calculation of the lease liabilities and right of use assets when the Company is reasonably certain to exercise the option. Office and Storage Space On November 1, 2021 the Company entered into a month-to-month lease agreement with Ranger Enterprises, LLC, located in Seymour, Indiana, to store product inventory at this satellite location. The Company made payments on this lease in the amount of $19,959. The lease was terminated in June 2022. On November 11, 2021 the Company entered into a month- to-month lease agreement with FFE Solutions Group, located in Salt Lake City Utah, to store additional product inventory at this satellite location. The Company made payments on this lease in the amount of $19,108. This lease was terminated in April 2022. On June 10, 2022, the Company entered into a Lease Agreement (the “2022 Lease”) with Just Pick for approximately 21,332 rentable square feet combined in the office building and warehouse located at 4460 Old Dixie Highway, Grant-Valkaria, Florida 32949 (the “Premises”), together with all improvements thereon. The Company must pay Just Pick base rent equal to $ 17,777 18,666 19,554 20,443 22,221 23,999 4.5 190,541 118,633 Cash flow information related to leases was as follows: Schedule of cash flow information related to leases October 31, 2023 October 31, 2022 Other Lease Information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ (190,541 ) $ (118,633 ) The following table summarizes the lease-related assets and liabilities recorded in the consolidated balance sheets on October 31, 2023, and 2022: Schedule of condensed balance sheet Lease Position October 31, 2023 October 31, 2022 Operating Leases Operating lease right-of-use assets $ 1,008,428 $ 1,198,969 Right of use liability operating lease, current portion $ 184,568 $ 166,051 Right of use liability operating lease, long term 866,207 1,050,776 Total operating lease liabilities $ 1,050,775 $ 1,216,827 The following table provides the future minimum operating lease payments as of October 31, 2023: Schedule of lessee operating lease liability maturity Operating Leases Future minimum operating lease liabilities on October 31, 2023 2024 $ 228,133 2025 238,800 2026 253,614 2027 274,946 2028 and thereafter 175,989 Total future undiscounted lease payments $ 1,171,482 Less: Imputed interest (120,707 ) Present value of lease liabilities $ 1,050,775 As of October 31, 2023, the Company had no additional leases which had not yet commenced.

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
Stockholders’ Equity	Oct. 31, 2023
Equity [Abstract]
Stockholders’ Equity	Note 8 – Stockholders’ Equity Common Shares During the year ended October 31, 2023, the Company issued 95,239 4,381 During the year ended October 31, 2023, the Company issued 19,048 130,478 During the year ended October 31, 2022, the Company issued 1,888 65,323 1,190,477 40,744 1,625,650 The Company’s stock-based compensation for Common Stock issued for services for the fiscal years ended October 31, 2023, and October 31, 2022, was $ 0 237,702 Restricted Stock Unit Awards During the year ended October 31, 2022, 5,870 172,379 2,130 59,862 On March 4, 2022, the Company’s Board approved the termination of the RSU agreements with the consent of the employees. At the time these agreements were terminated, there remained 1,564,166 4,457,875 Series A Convertible Preferred Stock Each share of the Series A Preferred Stock was initially convertible into 100 shares of Common Stock; However, it was affected by a subsequent reverse stock split also, the conversion rate was adjusted such that each share of the Series A Preferred Stock is convertible into approximately 0.3968 shares of Common Stock. 3,000,000 3,000,000 0.3968 1,190,477 Series B Convertible Preferred Stock The Company issued 900,000 15 15 The Majority Holders have the ability to cause a voluntary conversion of the Series B Preferred Stock into Common Stock at a conversion rate of 0.3968 shares of Common Stock per share of Series B Preferred Stock which may only occur on or after the following dates 18 month, 24 month, 36, month, 48 month, and 60 month anniversary of the original issuance date; and only up to 180,000 number of shares of Series B Preferred Stock on each of the these dates. Stock Options Summary of stock options information is as follows: Schedule of stock options Aggregate Aggregate Exercise Average Number Exercise Price Price Range Exercise Price Outstanding, October 31, 2021 7,143 $ 3,074,010 $ 191.52 602.28 $ 430.17 Granted 148,124 6,708,460 21.63 59.85 45.29 Exercised — — — — Cancelled, forfeited, or expired (2,778 ) (861,041 ) 191.52 545.58 309.95 Outstanding, October 31, 2022 152,489 8,921,429 21.63 602.28 58.50 Granted 300,188 5,314,460 10.08 20.72 17.66 Exercised — — — — Cancelled, forfeited, or expired (3,571 ) (154,481 ) 43.26 43.26 Outstanding, October 31, 2023 449,106 $ 14,081,408 $ 10.08 602.28 31.36 Exercisable, October 31, 2023 185,496 $ 9,194,852 $ 12.81 602.28 $ 49.57 The fair value of each option granted during the year ended October 31, 2023 and 2022 was estimated on the date of grant using the Black-Scholes option-pricing model with the weighted average assumptions in the following table: Schedule of assumptions 2023 2022 Expected dividend yield 0 % 0 % Expected option term (years) 6.25 10 10 Expected volatility 270.98 286.91 % 279.81 288.93 % Risk-free interest rate 3.47 4.34 % 1.74 3.13 % The expected term of options granted represents the period of time that options granted are expected to be outstanding. The expected volatility was based on the volatility in the trading of the Common Stock. The assumed discount rate was the default risk-free ten-year interest rate for US Treasury bills. During the year ended October 31, 2022, the Company recognized stock option expense of $ 6,043,312 1,716,795 9.52 50,000 On February 27, 2022, non-qualified stock options exercisable for up to 9,524 489,998 51.45 288.93 10 1.83 On April 22, 2022, non-qualified stock options exercisable for up to 3,571 106,499 29.82 286.00 10 2.90 On May 18, 2022, non-qualified stock options exercisable for up to 23,810 514,997 21.63 284.70 10 2.89 On August 1, 2022, non-qualified stock options exercisable for up to 1,190 29,000 24.36 281.14 10 2.60 On August 24, 2022, non-qualified stock options exercisable for up to 2,381 65,999 27.72 279.81 10 3.11 On March 4, 2022, options exercisable for up to an aggregate of 65,981 3,948,948 59.85 294.55 10 1.62 On June 24, 2022, non-qualified stock options exercisable for up to 41,667 17,858 23,809 1,504,990 36.12 283.12 10 3.13 During the year ended October 31, 2023, the Company recognized stock option expense of $ 3,168,430 3,904,525 8.99 0 On November 9, 2022, non-qualified stock options exercisable for up to 11,905 246,747 20.72 275.68 10 4.12 On November 9, 2022, non-qualified stock options exercisable for up to 142,857 180,000,000 3 2,960,968 20.72 275.68 10 4.12 10,387 15 On February 6, 2023, non-qualified stock options exercisable for up to 7,141 109,499 15.33 270.98 10 3.63 On February 6, 2023, non-qualified stock options exercisable for up to 47,620 50 729,988 15.33 270.98 10 3.63 On February 6, 2023, non-qualified stock options exercisable for up to 17,856 273,747 15.33 270.98 10 3.63 On February 6, 2023, non-qualified stock options exercisable for up to 9,524 100,000,000 145,998 15.33 270.98 10 3.63 On March 3, 2023, non-qualified stock options exercisable for up to 2,381 30,650 12.817 286.91 10 3.97 On March 19, 2023, non-qualified stock options exercisable for up to 11,904 217,498 18.27 286.15 10 3.47 On July 8, 2023, incentive stock options exercisable for up to 2,381 39,409 16.56 280.34 6.25 4.01 On August 1, 2023, incentive stock options exercisable for up to 39,095 These stock options have a ten-year term from the grant date, with the shares vesting as following: 1/4 of options on August 1, 2024 and thereafter 1/36 per month through August 1, 2027. 485,000 12.41 270.03 6.25 4.05 On August 22, 2023, incentive stock options exercisable for up to 7,524 These stock options have a ten-year term from the grant date, with the shares vesting as following: 1/4 of options on August 22, 2024 and thereafter 1/36 per month through August 22, 2027. 75,808 10.08 278.31 6.25 4.34 Common Stock Compensation Transition Plan During the second quarter of fiscal year 2021 the Board and executive management began cost reduction discussions, including the reduction of non-cash items such as equity compensation awards. Those discussions stalled primarily due to the focus on other corporate events of significant value. In the first and second fiscal quarters of 2022, the Board resumed discussions, assessments, and evaluations regarding the equity compensation awarded to its officers and employees. The Board ultimately approved a stock option program for equity awards granted to its officers and employees. The Compensation Committee of the Board finalized the program in February 2022 and approved it in March 2022. While evaluating and designing this program, the Compensation Committee did not utilize any aspects of value to the employees or other features. Therefore, the termination of the RSU program and the newly adopted stock option program were developed completely independent of each other and terminated and implemented, respectively, distinctly and simultaneously. Management concluded under ASC 718 these transactions are a cancelation and replacement whereby total compensation cost measured at the date of a cancellation and replacement is the portion of the grant-date fair value of the original award for which the service is expected to be rendered at that date plus the incremental cost resulting from the cancellation and replacement. Incremental cost is measured as the excess of the fair value of the replacement award over the fair value of the cancelled award at the cancellation date in which there was none since the fair value of the replacement award was less than the fair value of the canceled award. The outcomes of this decision and the transition on March 4, 2022, resulting in: (i) the termination of the RSU program for all executive officers and employees, consisting of 1,564,166 Warrants Summary Warrant Shares information is as follows: Schedule of warrant information Aggregate Aggregate Exercise Average Number Exercise Price Price Range Exercise Price Outstanding, October 31, 2021 151,139 $ 6,030,452 $ 39.90 $ 39.90 Granted — Exercised (40,743 ) (1,625,650 ) 39.90 39.90 Cancelled, forfeited, or expired — — — — Outstanding, October 31, 2022 110,396 4,404,802 39.90 39.90 Granted 132,152 9,544,205 12.39 126.00 72.22 Exercised — Cancelled, forfeited, or expired — — — — Outstanding, October 31, 2023 242,548 $ 13,949,006 $ 12.39 126.00 $ 57.51 Exercisable, October 31, 2023 242,548 $ 13,949,006 $ 12.39 126.00 $ 57.51 The outstanding warrants as of October 31, 2023 and 2022 have a weighted average remaining contractual life of 3.44 3.92 0 As part of the Company’s underwritten public offering in September 2021, the Company issued warrants to purchase a total of 193,036 39.90 40,743 1,625,650 The Company issued a common stock purchase warrant to purchase an aggregate of 95,240 63.00 84.00 105.00 126.00 23,810 The Company issued a common stock purchase warrant to purchase an aggregate of 17,524 5 14.70 The Company entered into a financial advisor and placement agent agreement in April 2023 with an advisor. As part of the consideration for the advisor’s services, the Company will issue warrants to purchase an aggregate of 17,143 15.33 During the twelve (12) month engagement period, the Company will grant the advisor warrants to purchase 1,429 shares of Common Stock each month. The Company issued the first six (6) months of warrants to purchase 8,572 shares of Common Stock upon the execution of the agreement and will issue monthly warrants each month at a rate of 1,429 warrants per month until 17,143 warrants have been issued in aggregate. 15,715 218,909 The Company entered into a financial advisor and placement agent agreement in August 2023 with an advisor. As part of the consideration for the advisor’s services, the Company issued warrants to purchase an aggregate of 3,673 12.39 The Company determined the fair value of the warrants using the Black-Scholes option-pricing model with the following assumptions: Schedule of fair value of the warrants Expected term (years) 5 Expected volatility 243.20 247.90 % Risk-free interest rate 3.81 4.18 % The expected term represents the contractual term of the warrant. The expected volatility was based on the Company’s observed equity volatility over the period matching the term of the warrant. The assumed discount rate was the risk-free rate based on the rate of treasury securities with the same or similar term as warrant.

Related-Party Transactions

Related-Party Transactions	12 Months Ended
Related-Party Transactions	Oct. 31, 2023
Related Party Transactions [Abstract]
Related-Party Transactions	Note 9 – Related-Party Transactions Revenue and Accounts Receivable During the fiscal year ended October 31, 2023, the Company recognized revenue of $ 10,828 During the fiscal year ended October 31, 2022, the Company recognized revenue of $ $ 68,139 Purchases and Accounts Payable During the fiscal year ended October 31, 2023, the Company purchased Products equal to $ 12,747,006 1,521,491 During the fiscal year ended October 31, 2022, the Company purchased Products equal to $ 1,505,390 no The KBI License agreement provides that KBI shall pay Bidi license fees equivalent to 50 As 712,524 2023, and $240,802 for reimbursement of insurance expense. Office Space and Other Leases On June 10, 2022, the Company entered into a Lease Agreement (the “2022 Lease”) with Just Pick, LLC for approximately 21,332 rentable square feet combined in the office building and warehouse located at 4460 Old Dixie Highway, Grant-Valkaria, Florida 32949 (the “Premises”), together with all improvements thereon. Just Pick, LLC is considered a related party to the Company because the Company’s Chief Science Officer and director, Mr. Nirajkumar Patel, owns and controls Just Pick, LLC. See also Note 7. We believe our office space is sufficient to meet our current needs. During the fiscal year ended October 31, 2021, the Company was part of a five-year lease agreement with Just Pick, LLC (a related party), which began on August 1, 2020. The Company was not yet being charged for the leased space under the terms and conditions of the lease between the Company and Just Pick, LLC. Accordingly, no payments were made on the lease during the fiscal year ended October 31, 2022. The lease ended in the same year of signing the previously mentioned lease with Just Pick, LLC on June 10, 2022. Concentration of Purchases and Other Receivable - Related Party For the year ended October 31, 2023, 100% of the inventories of Products, consisting solely of the BIDI® Stick, were purchased from Bidi, a related party company that is owned by Nirajkumar Patel, our Chief Science and Regulatory Officer and director, in the amount of $ 12,747,006 1,505,390 On April 29, 2022, the Company and Bidi agreed to cancel the $2,295,000 inventory order paid in advance in fiscal year 2021 and this was a credit against the accounts payable due to Bidi. Inventory quality control expenses were paid by the Company on behalf of Bidi during the year ended October 31, 2022, in the amount of approximately $723,000, and were offset as a credit against the accounts payable balance-related party. A credit of $2,924,655 was applied on August 1, 2022, resulting in a related-party receivable balance due from Bidi of $ 2,134,413 , to be applied on future product orders. On October 31, 2022, the Company and Bidi agreed to a return for short-coded or expiring inventory. An additional credit of $ 1,543,545 and $108,841 for recycling cost was applied on October 31, 2022, to the related-party receivable balance due from Bidi. As of October 31, 2022, the Company has a related-party receivable balance due from Bidi of $3,704,132, in which $1,539,486 of the receivable is classified as current and $2,164,646 is classified as non-current. The receivable balance will be realized though Bidi applying 5% credits on all future orders of product until the entire balance is extinguished. On October 31, 2023, the remaining related-party receivable balance from Bidi of $2,954,470 was applied against our related party accounts payable balance . After no

Income Tax

Income Tax	12 Months Ended
Income Tax	Oct. 31, 2023
Income Tax Disclosure [Abstract]
Income Tax	Note 10 – Income Tax The Company is subject to federal income taxes and state income tax in the U.S. Significant judgment is required in determining the provision for income taxes and income tax assets and liabilities, including evaluating uncertainties in the application of accounting principles and complex tax laws. The Tax Cuts and Jobs Act (the “Tax Act”) was enacted on December 22, 2017 and reduced the U.S. federal corporate tax rate from 35 21 4.458 Significant components of the tax expense (benefit) recognized in the accompanying statements of operations for the years ended October 31, 2023, and October 31, 2022, are as follows: Schedule of components of income tax expense October 31, 2023 2022 Current Tax Expense: Federal $ — $ — State 2,348 (18,317 ) Total Current Tax Expense 2,348 (18,317 ) Deferred Tax Expense: Federal — — State — — Total Deferred Tax Expense — — Tax provision: Federal — — State 2,348 (18,317 ) Total 2,348 (18,317 ) Total net deferred taxes are comprised of the following on October 31, 2022, and October 31, 2023: Schedule of deferred tax assets and liabilities October 31, 2023 2022 Deferred Tax Assets: Stock Compensation Expense – NQSO $ 2,069,641 $ 1,694,324 Other 499,203 362,170 Net Operating Loss Carryforwards 4,998,800 2,582,061 Total Deferred Tax Asset 7,567,644 4,638,555 Deferred Tax Liabilities: Prepaid Expenses (27,497 ) (92,420 ) Right of Use Asset (220,859 ) (259,866 ) Total Deferred Tax Liabilities (248,356 ) (352,286 ) Less: Valuation Allowance (7,319,288 ) (4,286,269 ) Net Deferred Tax Asset — — The Company has Federal NOL carryforwards of approximately $23.8 million and state NOL carryforwards of approximately $186,000. With the changes instituted by the CARES Act, the Federal NOLs have an indefinite life and will not expire. The Company’s federal and state tax returns for the 2022 and 2021 tax years generally remain subject to examination by U.S. and various state authorities. A valuation allowance is recorded to reduce the deferred tax asset if, based on the weight of the evidence, it is more likely than not that some portion or all the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, management has determined that a valuation allowance of $ 7,319,288

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Oct. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 11 – Commitments and Contingencies The Company follows ASC 450-20, Los Contingencies, no Consulting Agreements On March 17, 2021, the Company entered into a consulting agreement with Russell Quick, pursuant to which the Company granted stock options exercisable for up to 1,985 602.28 190,000 On December 1, 2021, the Company and Russell Quick agreed to renew his consulting agreement for one year, pursuant to which on May 18, 2022, the Company granted non-qualified stock options exercisable for up to 23,810 10 21.63 33,871 On February 4, 2022, the Company entered into a Consulting Agreement with Oakhill Europe Ltd (“Oakhill Europe”), pursuant to which the Company engaged Oakhill Europe to provide strategic advising and negotiation assistance for potential international distribution agreements (collectively, the “Oakhill Services”), in exchange for a $15,000 monthly retainer, incentive compensation bonuses of up to $175,000, and an incentive compensation bonus value of $75,000 paid in fully-vested non-qualified stock options, upon the achievement of certain events approved amending the Consulting Agreement for Oakhill Europe, in order to modify the previously granted stock option award from “ 75,000 3,572 1,786 1,786 The option shares are exercisable at a price of $ 29.82 The option shares issued to Oakhill Europe were cancelled on February 1, 2023. On August 1, 2022, the Company approved the grant of a stock option award to an employee, to acquire up to 1,191 24.36 On August 24, 2022, Company approved amending the Consulting Agreement for Mark Thoenes, the Company’s then Interim Chief Financial Officer, in order to extend its term, modify the vesting terms of the previously granted stock option award, and approved the grant of a stock option award to acquire up to 2,381 27.72 On October 28, 2022, The Company entered into a settlement agreement with a customer in the amount of $ 150,000 Executive Compensation On May 28, 2020, the Board approved cash bonus awards to each of Nirajkumar Patel, the Company’s then Chief Executive Officer, and Eric Mosser, the Company’s then Chief Operating Officer. With respect to the Chief Executive Officer, the Board approved a cash bonus award equal to $30,000 for every $25 million in gross revenues generated by the Company. With respect to the Chief Operating Officer, the Board approved a cash bonus award equal to $20,000 for every $25 million in gross revenues generated by the Company. On May 28, 2020, the Board also approved an equity bonus award for each of the Chief Executive Officer and the Chief Operating Officer. With respect to the Chief Executive Officer, the Board approved an award of 358 restricted shares of the Common Stock for every $50 million in accumulated gross revenues generated by the Company. With respect to the Chief Operating Officer, the Board approved an award of 298 restricted shares of the Common Stock for every $50 million in accumulated gross revenues generated by the Company. During the quarter ended April 30, 2022, the $ 125 50,000 On March 4, 2022, the Board terminated all future cash and equity bonus awards for the Company’s Chief Executive Officer and its Chief Operating Officer. On March 5, 2022, the Company granted a stock option award to Nirajkumar Patel, then the Company’s Chief Executive Officer, to acquire up to 28,572 shares of Common Stock under the Company’s 2020 Stock and Incentive Compensation Plan, as partial compensation for Mr. Patel’s services as Chief Executive Officer. The option shares are exercisable at a price of $59.85 per share, which equaled the closing price of the Common Stock as of the date immediately prior to the grant date. The issuances were exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof as a transaction not involving a public offering. On March 5, 2022, the Company granted stock option awards to Eric Mosser, the Company’s then Chief Operating Officer, to acquire up to 23,810 shares of Common Stock under the Company’s 2020 Stock and Incentive Compensation Plan, as partial compensation for Mr. Mosser’s services as Chief Operating Officer. The option shares are exercisable at a price of $59.85 per share, which equaled the closing price of the Common Stock as of the date immediately prior to the grant date. The issuances were exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof as a transaction not involving a public offering. On June 24, 2022, the Company granted a stock option award to Nirajkumar Patel, Chief Science and Regulatory Officer, to acquire up to 11,905 36.12 On June 24, 2022, the Company granted stock option awards to Eric Mosser, the Company’s then President and Chief Operating Officer, to acquire up to 11,905 36.12 QuikfillRx Service Agreement On March 31, 2020, the Company entered into a service agreement (the “Service Agreement”) with QuikfillRx LLC, a Florida limited liability company (“QuikfillRx”), whereby QuikfillRx provides the Company with certain services and support relating to sales management, website development and design, graphics, content, public communication, social media, management and analytics, and market and other research (collectively, the “Services”). The Services are provided by QuikfillRx as requested from time to time by the Company. On June 2, 2020, the Company entered into the First Amendment to the Service Agreement (the “First Amendment”) with QuikfillRx. Effective as of March 16, 2021, the Company entered into the Second Amendment to Service Agreement (the “Second Amendment”) with QuikfillRx. Effective as of September 17, 2021, the Company entered into the Third Amendment to the Service Agreement (the “Third Agreement”) with QuikfillRx. Effective as of June 24, 2022, the Company entered into the Fourth Amendment to the Service Agreement (the “Fourth Agreement” and, collectively with the First Amendment, Second Amendment, Third Amendment, and the Service Agreement, the “Amended Service Agreement”) with QuikfillRx. Pursuant to the terms of the Amended Service Agreement, the parties agreed to the following “General Compensation” payments: (i) for the Services provided in March 2020, the Company paid QuikfillRx an amount equal to $86,000; (ii) for the Services provided in April 2020, the Company paid QuikfillRx an amount equal to $100,000; (iii) each calendar month commencing May 2020 through October 2020, the Company paid QuikfillRx an amount equal to $100,000 per month for the Services to be performed during such calendar month; (iv) for each calendar month between November 1, 2020 and October 31, 2021, the Company paid QuikfillRx $125,000 per month for the Services to be performed during such calendar month; (iv) for the period between November 1, 2021 and June 30, 2022, the Company paid QuikfillRx $150,000 per month for the Services to be performed during such calendar month; (v) for the period between July 1, 2022 and October 31, 2024, the Company will pay QuikfillRx $125,000 per month for the Services to be performed during such calendar month; and (vi) parties acknowledged that as a result of extensions to the term of the Service Agreement , such term of the Original Agreement will end on October 31, 2023. The parties have agreed to extend such term for an additional one year until October 31, 2024. In addition, the Company will pay the following quarterly bonuses: ● An amount equal to 0.9% of the Applicable Gross Quarterly Sales (as defined in the Amended Service Agreement), which amount shall, at the Company’s option be paid in (a) cash or (b) shares of the Company’s Common Stock, or (c) a combination of cash and Common Stock. ● An amount equal to 0.27% of the Applicable Gross Quarterly Sales, which amount must be paid in cash. During fiscal year 2023, the Company accrued approximately $ 81,300

Subsequent Events

Subsequent Events	12 Months Ended
Subsequent Events	Oct. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 12 – Subsequent Events Reverse Stock Split On January 22, 2024, the Company filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to affect a 1-for-21 reverse stock split (the “2024 Reverse Stock Split”) of the shares of the Common Stock. The 2024 Reverse Stock Split was effective on January 25, 2024 on the Nasdaq Stock Market. No fractional shares were issued in connection with the 2024 Reverse Stock Split. Any fractional shares of our Common Stock that would have otherwise resulted from the 2024 Reverse Stock Split were rounded up to the nearest whole number. In connection with the 2024 Reverse Stock Split, the Board approved appropriate and proportional adjustments to all outstanding securities or other rights convertible or exercisable into shares of the Common Stock, including, without limitation, all preferred stock, warrants, options, and other equity compensation rights. All historical share and per-share amounts reflected throughout the accompanying consolidated financial statements and other financial information in this Report have been retroactively adjusted to reflect the 2024 Reverse Stock Split as if the split occurred as of the earliest period presented. The par value per share of the Common Stock was not affected by the 2024 Reverse Stock Split. Repayment of AJB Note On December 1, 2023, the Company repaid all amounts due and owing under the Note to AJB in full, in an aggregate amount, including accrued interest, equal to $ 650,181 Receivables Purchase Transactions On November 29, 2023, the Company entered into two receivables purchase transactions pursuant to: (i) a Future Receivables Sale and Purchase Agreement, dated November 29, 2023, between Clearview Funding Solutions LLC (“Clearview”) and the Company (the “Clearview Agreement”), and (ii) a Future Receivables Sale and Purchase Agreement, dated November 29, 2023, between Mr. Advance LLC (“Advance”) and the Company (the “Advance Agreement”). Pursuant to the Clearview Agreement, the Company sold future receivables in the principal amount of $ 864,000 600,000 264,000 36,520 563,480 Pursuant to the Advance Agreement, the Company sold future receivables in the principal amount of $ 864,000 600,000 264,000 36,035 563,965 Common Stock Transaction On December 15, 2023 the Company issued 16,667 Stock Options Transactions On February 8, 2024 (the "Grant Date"), Barry M. Hopkins received a 10-year incentive stock option grantto purchase 63,881 shares of Common Stock in partial consideration of his employment services to the Company. The exercise price of such grant option is $5.25 per share, equal to the fair market value of the Issuer's cCommon sStock on November 9, 2023, which is the effective date of the Reporting Person's Mr. Hopkins’ employment agreement with the IssuerCompany. The option shall vest over four years. One-quarter of the option shall vest on the first anniversary of the Ggrant Ddate and afterward shall vest monthly at the rate of 1/36 per month until fully vested. In connection with his appointment to the Company’s board of directors, on May 30, 2023, James P. Cassidy received a 10-year non-qualified stock option to purchase 5,953 shares of Common Stock with an exercise price of $11.76 per share, the fair market value of the Common Stock on May 30, 2023. In connection with Mr. Cassidy’s resignation from the board of directors on January 25, 2024, he agreed that such option should be terminated and cancelled.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	12 Months Ended
	Oct. 31, 2023
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the financial statements of the Company’s wholly-owned subsidiaries, Kaival Labs and Kaival Brands International. Intercompany transactions are eliminated.
Basis of Presentation	Basis of Presentation This summary of significant accounting policies is presented to assist in understanding the Company’s consolidated financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America (“GAAP”) and have been consistently applied in the preparation of the consolidated financial statements.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.
Cash	Cash The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. There were no The Federal Deposit Insurance Corporation (“FDIC”) insures deposits according to the ownership category in which the funds are insured and how the accounts are titled. The standard deposit insurance coverage limit is $ 250,000 252,586 2,912,793
Advertising and Promotion	Advertising and Promotion All advertising, promotion and marketing expenses, including commissions, are expensed when incurred.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Receivables are stated at cost, net of an allowance for doubtful accounts. The Company establishes an allowance for doubtful accounts based on the management’s assessment of the collectability of accounts receivable. A considerable amount of judgment is required in assessing the amount of the allowance and the Company considers the historical level of credit losses and collection history and applies percentages to aged receivable categories. The Company makes judgments about the creditworthiness of debtors based on ongoing credit evaluations and monitors current economic trends that might impact the level of credit losses in the future. If the financial condition of the debtors were to deteriorate, resulting in their inability to make payments, a larger allowance may be required. As of October 31, 2023, based upon management’s assessment of the accounts receivable aging and the customers’ payment history, the Company has determined that no allowance for doubtful accounts is required. The Company also had no On January 22, 2024, the FDA issued an MDO on Bidi Vapor’s “Classic” BIDI ® Stick PMTA. The Company evaluated the impact of this MDO to the financial statements and recorded an estimated accrual for potential customer returns of the “Classic” products of $ 113,243
Inventories	Inventories All product inventory is purchased from a related party, Bidi. Inventories are stated at the lower of cost and net realizable value. Cost includes all costs of purchase and other costs incurred in bringing the inventories to their present location and condition. The Company determines cost based on the first-in, first-out (“FIFO”) method. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. As of October 31, 2023, the inventories only consisted of finished goods and were located in three locations; the Kaival main warehouse and two customer warehouses whose service agreements are on a consignment basis with Kaival. During fiscal year 2023, the Company had a write-off of $ 105,057 no On January 22, 2024, the FDA issued an MDO on Bidi Vapor’s “Classic” BIDI ® Stick PMTA. The Company evaluated the impact of this MDO to the financial statements and recognized a full reserve for all remaining “Classic” products on hand amounting to $381,512 as of October 31, 2023 in order to comply with ASC 855 Subsequent Events. See Note 12.
Revenue Recognition	Revenue Recognition The Company adopted ASC 606, Revenue from Contracts with Customers
Deferred Revenue	Deferred Revenue The Company accepts partial payments for orders from wholesale customers, which it holds as deposits or deferred revenue, until the Company has received full payment and orders are shipped to the customer. Revenue for these orders is recognized at the time of shipment to the customer. As of October 31, 2023, and October 31, 2022, the Company has $ 0 44,973 0 235,274
Customer Refunds	Customer Refunds In the normal course of business, the Company issues credits for product returns and certain customer incentives related to rebates, discounts and promotions. When such credits exceed amounts receivable from customers, the Company recognizes such excess amounts as customer refunds which will be applied against future product purchases. As of October 31, 2023, and October 31, 2022, the Company had $ 392,406 0
Products Revenue	Products Revenue The Company generates products revenue from the sale of the Products (as defined above) to non-retail customers. The Company recognizes revenue at a point in time based on management’s evaluation of when performance obligations under the terms of a contract with the customer are satisfied and control of the Products has been transferred to the customer. In most situations, transfer of control is considered complete when the products have been shipped to the customer. The Company determined that a customer obtains control of the Product upon shipment when title of such product and risk of loss transfer to the customer. The Company’s shipping and handling costs are fulfillment costs, and such amounts are classified as part of cost of sales. The Company offers credit sales arrangements to non-retail (or wholesale) customers and monitors the collectability of each credit sale routinely. Revenue is measured by the transaction price, which is defined as the amount of consideration expected to be received in exchange for providing goods to customers. The transaction price is adjusted for estimates of known or expected variable consideration, which includes refunds and returns as well as incentive offers and promotional discounts on current orders. Estimates for sales returns are based on, among other things, an assessment of historical trends, information from customers, and anticipated returns related to current sales activity. These estimates are established in the period of sale and reduce revenue in the period of the sale. Variable consideration related to incentive offers and promotional programs are recorded as a reduction to revenue based on amounts the Company expects to collect. Estimates are regularly updated, and the impact of any adjustments are recognized in the period the adjustments are identified. In many cases, key sales terms such as pricing and quantities ordered are established at the time an order is placed and incentives have very short-term durations. Amounts billed and due from customers are short term in nature and are classified as receivable since payments are unconditional and only the passage of time related to credit terms is required before payments are due. The Company does not grant payment financing terms greater than one year. Payments received in advance of revenue recognition are recorded as deferred revenue, as noted above.
Royalty Revenue	Royalty Revenue On June 13, 2022, KBI entered into the PMI License Agreement with PMPSA, effective as of May 13, 2022 (the “PMI Commencement Date”). Pursuant to the PMI License Agreement, KBI granted PMPSA an exclusive irrevocable license to use its technology, documentation, and intellectual property to make, distribute, and sell disposable nicotine e-cigarettes Products based on the intellectual property in certain international markets set forth in the PMI License Agreement (the “PMI Markets”). The Company has the exclusive international distribution rights to the Products and, in order to allow KBI to fulfill its obligations set forth in the PMI License Agreement, has contributed the international distribution rights for the PMI Markets to KBI as set forth in a Capital Contribution Agreement, dated June 10, 2022. The sublicense granted to PMPSA is exclusive in the PMI Markets and neither KBI nor any of its affiliates can sell, promote, use, or distribute any competing products in the PMI Markets for the duration of the term of the PMI License Agreement and any Sell-Out Period (as defined in the PMI License Agreement). PMSPA will be responsible for any regulatory filings necessary to sell the Products in the PMI Markets. Both KBI and PMPSA agree to work together in the registration and maintenance of the Intellectual Property, but KBI will bear all cost and expense to implement the registration strategy. Finally, PMPSA has agreed to potential future development services with KBI in the PMI Markets and has been granted certain rights with respect to potential future products. The initial term of the PMI License Agreement is five (5) years and automatically renews for an additional five-year period unless PMPSA has failed to meet the agreed upon minimum key performance indicators set forth in the PMI License Agreement, in which case the PMI License Agreement will automatically terminate at the end of the initial license term. In consideration for the grant of the licensed rights, PMPSA agreed to pay to KBI a royalty equal to a percentage of the base price of the first sale of each unit of Product manufactured. In addition, before the launch of the first product in a market and each anniversary of such launch, PMPSA agrees to pre-pay to KBI a guaranteed minimum royalty based on the estimated royalties payable by PMPSA to KBI in relation to all markets in the twelve (12)-month period following the first launch or each successive anniversary of the first launch, subject to an aggregate maximum guaranteed royalty payment for all markets for each applicable twelve (12)-month period. PMPSA may require modification of certain products to be sold under the PMI Licensing Agreement to be modified for a PMI Market. Pursuant to the PMI Licensing Agreement, PMPSA has absolute discretion over sales, marketing, product branding and packaging pertaining to sales in the PMI Markets, as well as the right to select the specific PMI Markets in which to launch commercialization and determine what product types are to be promoted in each market, subject to sales and marketing plans and annual business plans set by PMPSA and certain expansion criteria agreed between PMPSA and KBI. Royalty revenue earned from the PMI License Agreement is recognized in the period the sales of the Product manufactured occurs. As of October 31, 2023, amounts receivable from PMPSA in connection with the PMI License Agreement totaled $ 1,002,196 289,672 712,524 The PMI License Agreement contains customary representations, warranties, covenants, and indemnification provisions; however, KBI’s liability under the PMI License Agreement is capped at the greater of: (i) Ten Million Dollars ($ 10,000,000 30,000,000 On June 10, 2022, Bidi entered into a License Agreement (the “KBI License Agreement”) with KBI, pursuant to which KBI has the exclusive irrevocable license to use Bidi’s licensed intellectual property to the extent necessary for KBI to fulfill its obligations set forth in the PMI Licensing Agreement. Such irrevocable license includes: (i) the right of KBI to grant sub-licenses to PMPSA under the PMI License Agreement for the express purposes set forth in the PMI License Agreement, but for no other purpose; (ii) the right of KBI to grant to PMPSA the right to grant sub-sub-licenses in the manner set forth in the PMI License Agreement, but for no other purpose; and (iii) certain branding rights to the extent (but only to the extent) necessary to permit KBI to perform its obligations to PMPSA as set forth in the PMI License Agreement. On August 12, 2023, the Company executed and entered into a Deed of Amendment No. 1 (the “PMI License Amendment”) with PMPSA, Bidi and KBI. Pursuant to the PMI License Amendment (which has an effective date of June 30, 2023), the following material changes have been made to the PMI License Agreement: 1. Royalty Rate. The royalty paid by PMPSA to KBI will no longer be based on sales price of the Product being sold, but rather on the volume of liquid contained within Product being sold. The royalty will be on a sliding scale of between $0.08 to $0.16 per sale based on the volume of liquid contained in the Product, increasing to between $0.10 to $0.20 per sale upon meeting certain sales milestones. 2. Elimination of Certain Potential Royalty Adjustments. Certain potential adjustments to the royalties receivable by KBI as provided for in the PMI License Agreement have been eliminated. 3. Guaranteed Royalty. The guaranteed royalty payment owed to KBI under the PMI License Agreement has been eliminated. Instead, royalties will be paid on a quarterly basis going-forward based on actual sales. Any unpaid guaranteed royalty has been cancelled. 4. Insurance Tail Requirements. KBI’s requirement to keep certain tail insurance after the expiration or termination of the PMI Licensing Agreement was reduced from 6 years to 2 years. 5. Markets. The identification of the PMI Markets that PMI may enter has been expanded to cover certain additional territories. 6. Net Reconciliation Payment to KBI. As a result of the changes to the PMI License Agreement described in paragraphs 1 thought 3 above, the value of such changes was calculated and reconciled as of the date of commencement of the PMI Licensing Agreement through June 30, 2023. On September 8, 2023, the Company received the Net Reconciliation Payment from PMPSA of $ 134,981 The KBI License Agreement provides that KBI shall pay Bidi license fees equivalent to 50% of the adjusted earned royalty payments, after any offsets due to jointly agreed costs such development costs incurred for entry to specific international markets. During the year ended October 31, 2023, the Company paid license fees of approximately $150,000 to Bidi. As of October 31, 2023 and 2022, no additional license fees are owed to Bidi.
Concentration of Revenues and Accounts Receivable	Concentration of Revenues and Accounts Receivable For the fiscal year 2023, (i) approximately 15% or $ 1,986,970 1,842,511 1,817,310 1,759,563 1,501,439 For the fiscal year 2022, (i) approximately 30% or $ 3,945,534 ® 1,892,245 1,472,888 FAVS Business LLC with an outstanding balance of $ 302,400 300,590 164,987 Favs Business with an outstanding balance of $ 375,425 85,510
Share-Based Compensation	Share-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments (share-based payments, referred to herein as “SBP”) based on the grant-date fair value of the award. That cost is recognized over the period during which a recipient is required to provide service in exchange for the SBP award—the requisite service period (vesting period). For SBP awards subject to performance conditions, compensation is not recognized until the performance condition is probable of occurrence. The grant-date fair value of share options is estimated using the Black-Scholes-Merton option-pricing model based on certain assumptions which include the expected term, expected volatility and discount rate. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The expected volatility is based on the volatility in the trading of the Common Stock over the expected term of the award. The assumed discount rate is the default risk-free ten-year interest rate for U.S. Treasury bills.
Net Loss Per Share	Net Loss Per Share Basic net income (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period, without consideration of potential common stock equivalents. Diluted net income (loss) per share is calculated by dividing net income (loss) available to common stockholders by the weighted average number of common stock outstanding plus common share equivalents from conversion of dilutive stock options and warrants using the treasury method and preferred stock using the as-converted method, except when antidilutive. In the event of a net loss, the effects of all potentially dilutive shares are excluded from the diluted net loss per share calculation as their inclusion would be antidilutive. For the year ended October 31, 2023 the outstanding common stock equivalents excluded from the computation of diluted net loss were 449,106 242,548 357,120 152,489 110,396
Income Tax	Income Tax Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes related primarily to differences between the recorded book basis and the tax basis of assets and liabilities for financial and income tax reporting. Deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes are also recognized for operating losses that are available to offset future taxable income and tax credits that are available to offset future federal income taxes. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material adverse effect on the Company’s financial condition, results of operations, or cash flow. The Company has Federal net operating loss (“NOL”) carryforwards, consisting of total deferred tax assets, totaling approximately $ 23.8 0.2 7,319,289 4,286,289
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. ASC 820, Fair Value Measurements and Disclosures ● Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. ● Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. ● Level 3 – Inputs that are both significant to the fair value measurement and unobservable. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of October 31, 2023 and 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, restricted cash, accounts receivable, accounts payable and accrued expenses. As of October 31, 2023, and 2022, the Company did not have any financial assets or liabilities measured and recorded at fair value on a recurring basis.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplified the accounting for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplified the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that required entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revised the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revised the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (“EPS”) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. ASU 2020-06 was effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption was permitted. The Company has elected to early adopt ASU 2020-06 effective beginning November 1, 2022. There was no impact on the consolidated financial statements as a result of adopting this standard. The Company does not believe that any recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements. However, In March 2022, the FASB issued ASU 2022-02, “Financial Instruments-Credit Losses (Topic 326), Troubled Debt Restructurings and Vintage Disclosures.” ASU 2022-02 addresses areas identified by the FASB as part of its post-implementation review of the credit losses standard (ASU 2016-13) that introduced the current expected credit loss (“CECL”) model. The amendments eliminate the accounting guidance for troubled debt restructurings (“TDRs”) by creditors that have adopted the CECL model and enhance the disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty. In addition, the amendments require a public business entity to disclose current-period gross write-offs for financing receivables and net investment in leases by year of origination in the vintage disclosures. The amendments in this ASU should be applied prospectively, except for the transition method related to the recognition and measurement of TDRs, where an entity has the option to apply a modified retrospective transition method resulting in a cumulative-effect adjustment to retained earnings in the period of adoption. This is not effective for the Company until November 1, 2023

Acquisition of GoFire Assets (T

Acquisition of GoFire Assets (Tables)	12 Months Ended
Acquisition of GoFire Assets (Tables)	Oct. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of consideration paid	Schedule of consideration paid Common Stock $ 1,119,800 Series B Preferred Stock 9,047,980 Common Stock Warrants 1,059,523 Transaction Costs 568,672 Total consideration $ 11,795,975

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	12 Months Ended
Intangible Assets, net (Tables)	Oct. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of future amortization expense of intangible assets	Schedule of future amortization expense of intangible assets 2024 $ 786,398 2025 786,398 2026 786,398 2027 786,398 2028 786,398 Thereafter 7,536,319 Total $ 11,468,309

Loans Payable (Tables)

Loans Payable (Tables)	12 Months Ended
Loans Payable (Tables)	Oct. 31, 2023
Debt Disclosure [Abstract]
Schedule of loan agreements	Schedule of loan agreements Purchase Payment Payment Deferred Inception Date Price Purchased Amount Outstanding Balance frequency Rate Finance Fees May 9, 2023 $ 400,000 $ 580,000 $ 53,709 Weekly 20,714 $ 3,434 May 9, 2023 400,000 580,000 80,467 Weekly 20,714 5,247 $ 800,000 $ 1,160,000 $ 134,176 $ 8,681

Leases (Tables)

Leases (Tables)	12 Months Ended
Leases (Tables)	Oct. 31, 2023
Leases
Schedule of cash flow information related to leases	Schedule of cash flow information related to leases October 31, 2023 October 31, 2022 Other Lease Information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ (190,541 ) $ (118,633 )
Schedule of condensed balance sheet	Schedule of condensed balance sheet Lease Position October 31, 2023 October 31, 2022 Operating Leases Operating lease right-of-use assets $ 1,008,428 $ 1,198,969 Right of use liability operating lease, current portion $ 184,568 $ 166,051 Right of use liability operating lease, long term 866,207 1,050,776 Total operating lease liabilities $ 1,050,775 $ 1,216,827
Schedule of lessee operating lease liability maturity	Schedule of lessee operating lease liability maturity Operating Leases Future minimum operating lease liabilities on October 31, 2023 2024 $ 228,133 2025 238,800 2026 253,614 2027 274,946 2028 and thereafter 175,989 Total future undiscounted lease payments $ 1,171,482 Less: Imputed interest (120,707 ) Present value of lease liabilities $ 1,050,775

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	12 Months Ended
Stockholders’ Equity (Tables)	Oct. 31, 2023
Equity [Abstract]
Schedule of stock options	Schedule of stock options Aggregate Aggregate Exercise Average Number Exercise Price Price Range Exercise Price Outstanding, October 31, 2021 7,143 $ 3,074,010 $ 191.52 602.28 $ 430.17 Granted 148,124 6,708,460 21.63 59.85 45.29 Exercised — — — — Cancelled, forfeited, or expired (2,778 ) (861,041 ) 191.52 545.58 309.95 Outstanding, October 31, 2022 152,489 8,921,429 21.63 602.28 58.50 Granted 300,188 5,314,460 10.08 20.72 17.66 Exercised — — — — Cancelled, forfeited, or expired (3,571 ) (154,481 ) 43.26 43.26 Outstanding, October 31, 2023 449,106 $ 14,081,408 $ 10.08 602.28 31.36 Exercisable, October 31, 2023 185,496 $ 9,194,852 $ 12.81 602.28 $ 49.57
Schedule of assumptions	Schedule of assumptions 2023 2022 Expected dividend yield 0 % 0 % Expected option term (years) 6.25 10 10 Expected volatility 270.98 286.91 % 279.81 288.93 % Risk-free interest rate 3.47 4.34 % 1.74 3.13 %
Schedule of warrant information	Schedule of warrant information Aggregate Aggregate Exercise Average Number Exercise Price Price Range Exercise Price Outstanding, October 31, 2021 151,139 $ 6,030,452 $ 39.90 $ 39.90 Granted — Exercised (40,743 ) (1,625,650 ) 39.90 39.90 Cancelled, forfeited, or expired — — — — Outstanding, October 31, 2022 110,396 4,404,802 39.90 39.90 Granted 132,152 9,544,205 12.39 126.00 72.22 Exercised — Cancelled, forfeited, or expired — — — — Outstanding, October 31, 2023 242,548 $ 13,949,006 $ 12.39 126.00 $ 57.51 Exercisable, October 31, 2023 242,548 $ 13,949,006 $ 12.39 126.00 $ 57.51
Schedule of fair value of the warrants	Schedule of fair value of the warrants Expected term (years) 5 Expected volatility 243.20 247.90 % Risk-free interest rate 3.81 4.18 %

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
Income Tax (Tables)	Oct. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of components of income tax expense	Schedule of components of income tax expense October 31, 2023 2022 Current Tax Expense: Federal $ — $ — State 2,348 (18,317 ) Total Current Tax Expense 2,348 (18,317 ) Deferred Tax Expense: Federal — — State — — Total Deferred Tax Expense — — Tax provision: Federal — — State 2,348 (18,317 ) Total 2,348 (18,317 )
Schedule of deferred tax assets and liabilities	Schedule of deferred tax assets and liabilities October 31, 2023 2022 Deferred Tax Assets: Stock Compensation Expense – NQSO $ 2,069,641 $ 1,694,324 Other 499,203 362,170 Net Operating Loss Carryforwards 4,998,800 2,582,061 Total Deferred Tax Asset 7,567,644 4,638,555 Deferred Tax Liabilities: Prepaid Expenses (27,497 ) (92,420 ) Right of Use Asset (220,859 ) (259,866 ) Total Deferred Tax Liabilities (248,356 ) (352,286 ) Less: Valuation Allowance (7,319,288 ) (4,286,269 ) Net Deferred Tax Asset — —

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)		12 Months Ended
	Sep. 08, 2023	Oct. 31, 2023	Oct. 31, 2022
Product Information [Line Items]
Cash equivalents and restricted cash		$ 0	$ 0
Cash FDIC insured amount		250,000
Cash, uninsured amount		252,586	2,912,793
Allowance for doubtful accounts			0
Accrual expense		113,243
Inventory Write-down		105,057
Inventory Valuation Reserves		0	0
Deposits from customers		0	44,973
Deferred income		0	235,274
Refunds due to various customers		$ 392,406	0
Royalty rate		The royalty paid by PMPSA to KBI will no longer be based on sales price of the Product being sold, but rather on the volume of liquid contained within Product being sold. The royalty will be on a sliding scale of between $0.08 to $0.16 per sale based on the volume of liquid contained in the Product, increasing to between $0.10 to $0.20 per sale upon meeting certain sales milestones.
Revenue not from contract with customer		$ 1,986,970	3,945,534
Revenue from sale		1,842,511
Total deferred tax assets		23,800,000
Total deferred tax liabilities		200,000
Valuation allowance		$ 7,319,289	$ 4,286,289
Stock Options [Member]
Product Information [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		449,106	152,489
Warrants [Member]
Product Information [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		242,548	110,396
Series B Convertible Preferred Stock [Member]
Product Information [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		357,120
Accounts Receivable [Member] \| FAVS [Member]
Product Information [Line Items]
Outstanding balance		$ 302,400
Accounts Receivable [Member] \| C Store Master [Member]
Product Information [Line Items]
Outstanding balance		300,590
Accounts Receivable [Member] \| Quik Trip Corporation [Member]
Product Information [Line Items]
Outstanding balance		164,987
FAVS [Member]
Product Information [Line Items]
Revenue not from contract with customer		1,817,310
C Store Master [Member]
Product Information [Line Items]
Revenue not from contract with customer		1,759,563
QuikTrip [Member]
Product Information [Line Items]
Revenue not from contract with customer		1,501,439
M M S Distro [Member]
Product Information [Line Items]
Revenue not from contract with customer			$ 1,892,245
GPM [Member]
Product Information [Line Items]
Revenue not from contract with customer			$ 1,472,888
Favs Business L L C [Member]
Product Information [Line Items]
Revenue not from contract with customer		375,425
Quik Trip Corporation [Member]
Product Information [Line Items]
Revenue from sale		85,510
PMI License Agreement [Member]
Product Information [Line Items]
Liabilities		10,000,000
Royalty payment		30,000,000
P M P S A [Member] \| PMI License Agreement [Member]
Product Information [Line Items]
License agreement amount		1,002,196
Royalty amount		289,672
Reimbursement amount		$ 712,524
Royalty payment received	$ 134,981

Acquisition of GoFire Assets (D

Acquisition of GoFire Assets (Details)	May 30, 2023 USD ($)
Business Acquisition [Line Items]
Common Stock	$ 1,119,800
Transaction Costs	568,672
Total consideration	11,795,975
Common Stock Warrants [Member]
Business Acquisition [Line Items]
Common Stock Warrants	1,059,523
Series B Preferred Stock [Member]
Business Acquisition [Line Items]
Series B Preferred Stock	$ 9,047,980

Acquisition of GoFire Assets _2

Acquisition of GoFire Assets (Details Narrative) - $ / shares	Oct. 31, 2023	May 30, 2023	Oct. 31, 2022
Business Acquisition [Line Items]
Preferred Stock, par value	$ 0.001	$ 0.001	$ 0.001
Series B Preferred Stock [Member]
Business Acquisition [Line Items]
Aggregate shares		900,000
Common Stock [Member]
Business Acquisition [Line Items]
Aggregate shares		95,239
Warrant [Member]
Business Acquisition [Line Items]
Aggregate shares		95,239

Intangible Assets, net (Details

Intangible Assets, net (Details)	Oct. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 786,398
2025	786,398
2026	786,398
2027	786,398
2028	786,398
Thereafter	7,536,319
Total	$ 11,468,309

Intangible Assets, net (Detai_2

Intangible Assets, net (Details Narrative)	12 Months Ended
Intangible Assets, net (Details Narrative)	Oct. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Cost of intangible assets	$ 11,795,975
Accumulated amortization of intangible asset	$ 327,666
Intangible assets useful life	15 years
Weighted average remaining useful life	14 years 7 months 6 days

Loans Payable (Details)

Loans Payable (Details)	Oct. 31, 2023 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Purchase Price	$ 800,000
Purchased Amount	1,160,000
Outstanding Balance	134,176
Deferred Finance Fees	8,681
May 9, 2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Purchase Price	400,000
Purchased Amount	580,000
Outstanding Balance	53,709
Payment Rate	20,714
Deferred Finance Fees	3,434
May 9, 2023 One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Purchase Price	400,000
Purchased Amount	580,000
Outstanding Balance	80,467
Payment Rate	20,714
Deferred Finance Fees	$ 5,247

Loans Payable (Details Narrativ

Loans Payable (Details Narrative) - USD ($)	12 Months Ended
Loans Payable (Details Narrative) - USD ($)	Oct. 31, 2023	May 20, 2023
Debt Instrument [Line Items]
[custom:CommitmentFeeShares]	19,048
Promissory note principal amount	$ 134,176
Westfield Bank [Member]
Debt Instrument [Line Items]
Promissory note principal amount		$ 342,001
Interest rate		7.79%
Remaining balance of debt		$ 152,000

Leases (Details)

Leases (Details) - USD ($)	12 Months Ended
Leases (Details) - USD ($)	Oct. 31, 2023	Oct. 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ (190,541)	$ (118,633)

Leases (Details 1)

Leases (Details 1) - USD ($)	Oct. 31, 2023	Oct. 31, 2022
Operating Leases
Operating lease right-of-use assets	$ 1,008,428	$ 1,198,969
Right of use liability operating lease, current portion	184,568	166,051
Right of use liability operating lease, long term	866,207	1,050,776
Total operating lease liabilities	$ 1,050,775	$ 1,216,827

Leases (Details 2)

Leases (Details 2) - USD ($)	Oct. 31, 2023	Oct. 31, 2022
Leases
2024	$ 228,133
2025	238,800
2026	253,614
2027	274,946
2028 and thereafter	175,989
Total future undiscounted lease payments	1,171,482
Less: Imputed interest	(120,707)
Present value of lease liabilities	$ 1,050,775	$ 1,216,827

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)			12 Months Ended
Leases (Details Narrative) - USD ($)	Nov. 11, 2021	Nov. 02, 2021	Oct. 31, 2023	Oct. 31, 2022
Lessee, Lease, Description [Line Items]
Leases, description	the Company entered into a month- to-month lease agreement with FFE Solutions Group, located in Salt Lake City Utah, to store additional product inventory at this satellite location. The Company made payments on this lease in the amount of $19,108. This lease was terminated in April 2022.	the Company entered into a month-to-month lease agreement with Ranger Enterprises, LLC, located in Seymour, Indiana, to store product inventory at this satellite location. The Company made payments on this lease in the amount of $19,959. The lease was terminated in June 2022.
Operating lease discount rate			4.50%
Office And Storage Space [Member]
Lessee, Lease, Description [Line Items]
Operating lease expense			$ 190,541	$ 118,633
Year One [Member]
Lessee, Lease, Description [Line Items]
Payment for rent			17,777
Year Two [Member]
Lessee, Lease, Description [Line Items]
Payment for rent			18,666
Year Three [Member]
Lessee, Lease, Description [Line Items]
Payment for rent			19,554
Year Four [Member]
Lessee, Lease, Description [Line Items]
Payment for rent			20,443
Year Five [Member]
Lessee, Lease, Description [Line Items]
Payment for rent			22,221
Year Six [Member]
Lessee, Lease, Description [Line Items]
Payment for rent			$ 23,999

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Equity Option [Member] - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Offsetting Assets [Line Items]
Aggregate number of shares outstanding, beginning	152,489	7,143
Aggregate exercise price outstanding, beginning	$ 8,921,429	$ 3,074,010
Average exercise price outstanding, beginning	$ 58.50	$ 430.17
Aggregate number, Granted	300,188	148,124
Aggregate exercise price, Granted	$ 5,314,460	$ 6,708,460
Average exercise price outstanding, Granted	$ 17.66	$ 45.29
Aggregate number, Exercised
Aggregate exercise price, Exercised
Exercise price range, Exercised
Average exercise price outstanding, Exercised
Aggregate number, Cancelled, forfeited, or expired	(3,571)	(2,778)
Aggregate exercise price, Cancelled, forfeited, or expired	$ (154,481)	$ (861,041)
Exercise price range, Cancelled, forfeited, or expired	$ 43.26
Average exercise price outstanding, Cancelled, forfeited, or expired	$ 43.26	$ 309.95
Aggregate number of shares outstanding, ending	449,106	152,489
Aggregate exercise price outstanding, ending	$ 14,081,408	$ 8,921,429
Average exercise price outstanding, ending	$ 31.36	$ 58.50
Aggregate number of shares outstanding, Exercisable	185,496
Aggregate exercise price, Exercisable	$ 9,194,852
Average exercise price outstanding, Exercisable	$ 49.57
Minimum [Member]
Offsetting Assets [Line Items]
Exercise price range outstanding, beginning	21.63	191.52
Exercise price range, Granted	10.08	21.63
Exercise price range, Cancelled, forfeited, or expired		191.52
Exercise price range outstanding, ending	10.08	21.63
Exercise price range, Exercisable	12.81
Maximum [Member]
Offsetting Assets [Line Items]
Exercise price range outstanding, beginning	602.28	602.28
Exercise price range, Granted	20.72	59.85
Exercise price range, Cancelled, forfeited, or expired		545.58
Exercise price range outstanding, ending	602.28	$ 602.28
Exercise price range, Exercisable	$ 602.28

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1)	12 Months Ended
Stockholders' Equity (Details 1)	Oct. 31, 2023	Oct. 31, 2022
Expected dividend yield	0%	0%
Expected option term (years)		10 years
Minimum [Member]
Expected option term (years)	6 years 3 months
Expected volatility	270.98%	279.81%
Risk-free interest rate	3.47%	1.74%
Maximum [Member]
Expected option term (years)	10 years
Expected volatility	286.91%	288.93%
Risk-free interest rate	4.34%	3.13%

Stockholders' Equity (Details 2

Stockholders' Equity (Details 2) - Warrant [Member] - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Aggregate number of shares outstanding, beginning	110,396	151,139
Aggregate exercise price outstanding, beginning	$ 4,404,802	$ 6,030,452
Exercise price range outstanding, beginning	$ 39.90	$ 39.90
Average exercise price outstanding, beginning	39.90	39.90
Average exercise price outstanding, Granted	72.22
Aggregate number, Exercised		(40,743)
Aggregate exercise price, Exercised		$ (1,625,650)
Exercise price range, Exercised		$ 39.90
Average exercise price outstanding, Exercised		$ 39.90
Aggregate number, Cancelled, forfeited, or expired
Aggregate exercise price,Cancelled, forfeited, or expired
Exercise price range, Cancelled, forfeited, or expired
Average exercise price outstanding, Cancelled, forfeited, or expired
Aggregate number, Granted	132,152
Aggregate exercise price, Granted	$ 9,544,205
Aggregate number of shares outstanding, ending	242,548	110,396
Aggregate exercise price outstanding, ending	$ 13,949,006	$ 4,404,802
Exercise price range outstanding, ending		$ 39.90
Average exercise price outstanding, ending	$ 57.51	$ 39.90
Aggregate number of shares outstanding, Exercisable	242,548
Aggregate exercise price, Exercisable	$ 13,949,006
Average exercise price outstanding, Exercisable	$ 57.51
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price range, Granted	12.39
Exercise price range outstanding, ending	12.39
Exercise price range, Exercisable	12.39
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price range, Granted	126
Exercise price range outstanding, ending	126
Exercise price range, Exercisable	$ 126

Stockholders' Equity (Details 3

Stockholders' Equity (Details 3)	12 Months Ended
Stockholders' Equity (Details 3)	Oct. 31, 2023
Equity [Abstract]
Expected term (years)	5 years
Expected volatility, minimum	243.20%
Expected volatility, maximum	247.90%
Risk-free interest rate, minimum	3.81%
Risk-free interest rate, maximum	4.18%

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)

1 Months Ended

12 Months Ended

Aug. 22, 2023

Aug. 02, 2023

Jul. 08, 2023

Mar. 19, 2023

Mar. 03, 2023

Feb. 06, 2023

Nov. 09, 2022

Aug. 24, 2022

Aug. 02, 2022

Jun. 24, 2022

May 18, 2022

Apr. 22, 2022

Mar. 04, 2022

Feb. 27, 2022

Apr. 30, 2023

Sep. 30, 2021

Oct. 31, 2023

Oct. 31, 2022

Aug. 31, 2023

Mar. 17, 2021

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common stock shares, issued

95,239

Common shares for services, value

$ 65,323

Share-based compensation

$ 0

237,702

Obligations value

59,862

Stock option expense recognized

3,168,430

6,043,312

Unrecognized expenses related to outstanding stock options

$ 3,904,525

$ 1,716,795

Weighted average remaining contractual life

8 years 11 months 26 days

9 years 6 months 7 days

Aggregate intrinsic value

$ 50,000

Expected term

5 years

Intrinsic value of outstanding options

$ 0

Unvested shares

1,564,166

Warrants purchase

193,036

Warrant exercise price

$ 39.90

$ 14.70

$ 602.28

Warrants exercised, shares

40,743

Proceeds from the exercise of warrants

$ 0

$ 1,625,650

Financial Advisor [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrant exercise price

$ 15.33

$ 12.39

Aggregate of shares of common stock

17,143

3,673

Warrant issued, description

During the twelve (12) month engagement period, the Company will grant the advisor warrants to purchase 1,429 shares of Common Stock
each month. The Company issued the first six (6) months of warrants to purchase 8,572 shares of Common Stock upon the execution of the
agreement and will issue monthly warrants each month at a rate of 1,429 warrants per month until 17,143 warrants have been issued in
aggregate.

Issued of warrants

15,715

Stock warrants expense

$ 218,909

Series A Convertible Preferred Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Reverse stock split description

the conversion rate
was adjusted such that each share of the Series A Preferred Stock is convertible into approximately 0.3968 shares of Common Stock.

Number of shares converted

3,000,000

Conversion price

$ 0.3968

Series A Convertible Preferred Stock [Member] | Kaival Holdings L L C [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares converted

3,000,000

Series B Preferred Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Preferred stock shares issued

900,000

Preferred stock redemption price per share

$ 15

Preferred stock liquidation preference per share

$ 15

Preferred stock, conversion basis

The Majority Holders have the ability to cause a voluntary conversion
of the Series B Preferred Stock into Common Stock at a conversion rate of 0.3968 shares of Common Stock per share of Series B Preferred
Stock which may only occur on or after the following dates 18 month, 24 month, 36, month, 48 month, and 60 month anniversary of the original
issuance date; and only up to 180,000 number of shares of Series B Preferred Stock on each of the these dates.

Employee Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shares issued

2,130

Restricted Stock Units (RSUs) [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share-based compensation

$ 172,379

Shares issued

5,870

Remaining unvested shares

1,564,166

Unamortized stock expenses

$ 4,457,875

Equity Option [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock option expense recognized

$ 6,043,312

Stock option exercisable

65,981

Fire value granted

$ 3,948,948

Share price

$ 59.85

Volatility rate

294.55%

Expected term

10 years

Interest rate

1.62%

Tranches 1 [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrant exercise price

$ 63

Tranches 2 [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrant exercise price

Tranches 3 [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrant exercise price

105

Tranches 4 [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrant exercise price

$ 126

Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common shares issued for services, shares

4,381

Number of shares issued for loan

19,048

Number of shares issued for loan value

$ 130,478

Common shares for services

1,888

Common shares for services, value

$ 2

Conversion of shares

1,190,477

Exercise of common stock warrants issued

40,744

Exercise of common stock warrants

$ 1,625,650

Number of shares converted

1,190,477

Stock option expense recognized

Stock option exercisable

23,810

Fire value granted

$ 1,504,990

Common Stock [Member] | Two Officers [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock option exercisable

41,667

Fire value granted

$ 17,858

Share price

$ 36.12

Volatility rate

283.12%

Expected term

10 years

Interest rate

3.13%

Vested shares

23,809

Common Stock [Member] | Two Consultants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock option exercisable

9,524

Fire value granted

$ 489,998

Share price

$ 51.45

Volatility rate

288.93%

Expected term

10 years

Interest rate

1.83%

Common Stock [Member] | One Consultants [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock option exercisable

9,524

2,381

3,571

Fire value granted

$ 145,998

$ 65,999

$ 106,499

Share price

$ 15.33

$ 27.72

$ 29.82

Volatility rate

270.98%

279.81%

286%

Expected term

10 years

Interest rate

3.63%

3.11%

2.90%

Total net revenues

$ 100,000,000

Common Stock [Member] | One Employee [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock option exercisable

39,095

2,381

1,190

23,810

Fire value granted

$ 485,000

$ 39,409

$ 29,000

$ 514,997

Share price

$ 12.41

$ 16.56

$ 24.36

$ 21.63

Volatility rate

270.03%

280.34%

281.14%

284.70%

Expected term

6 years 3 months

10 years

Interest rate

4.05%

4.01%

2.60%

2.89%

Stock option description

These stock options have a ten-year term
from the grant date, with the shares vesting as following: 1/4 of options on August 1, 2024 and thereafter 1/36 per month through August
1, 2027.

Common Stock [Member] | One Supplier [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock option exercisable

11,905

Fire value granted

$ 246,747

Share price

$ 20.72

Volatility rate

275.68%

Expected term

10 years

Interest rate

4.12%

Total options vested

$ 10,387

Gross profit percentage

15%

Common Stock [Member] | Two Supplier [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock option exercisable

142,857

Fire value granted

$ 2,960,968

Share price

$ 20.72

Volatility rate

275.68%

Expected term

10 years

Interest rate

4.12%

Total net revenues

$ 180,000,000

Gross profit margin period

3 years

Common Stock [Member] | Five Employees [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock option exercisable

7,141

Fire value granted

$ 109,499

Share price

$ 15.33

Volatility rate

270.98%

Expected term

10 years

Interest rate

3.63%

Common Stock [Member] | Two Senior Executives [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock option exercisable

47,620

Fire value granted

$ 729,988

Share price

$ 15.33

Volatility rate

270.98%

Expected term

10 years

Interest rate

3.63%

Vesting percentage

50%

Common Stock [Member] | Three Independent Board [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock option exercisable

17,856

Fire value granted

$ 273,747

Share price

$ 15.33

Volatility rate

270.98%

Expected term

10 years

Interest rate

3.63%

Common Stock [Member] | One Interim Senior Executive [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock option exercisable

2,381

Fire value granted

$ 30,650

Share price

$ 12.817

Volatility rate

286.91%

Expected term

10 years

Interest rate

3.97%

Common Stock [Member] | Two Independent Board [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock option exercisable

11,904

Fire value granted

$ 217,498

Share price

$ 18.27

Volatility rate

286.15%

Expected term

10 years

Interest rate

3.47%

Common Stock [Member] | One Senior Executive [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock option exercisable

7,524

Fire value granted

$ 75,808

Share price

$ 10.08

Volatility rate

278.31%

Expected term

6 years 3 months

Interest rate

4.34%

Stock option description

These stock options have a ten-year term from
the grant date, with the shares vesting as following: 1/4 of options on August 22, 2024 and thereafter 1/36 per month through August 22,
2027.

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Intrinsic value of outstanding options

$ 0

Weighted average remaining contractual life

3 years 5 months 8 days

3 years 11 months 1 day

Class of Warrant or Right, Outstanding

23,810

Warrant To Purchase [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Aggregate of shares of common stock

95,240

Warrant To Purchase 1 [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Aggregate of shares of common stock

17,524

Warrant exercisable period

5 years

Related-Party Transactions (Det

Related-Party Transactions (Details Narrative) - USD ($)	12 Months Ended
Related-Party Transactions (Details Narrative) - USD ($)	Oct. 31, 2023	Oct. 31, 2022
Related Party Transaction [Line Items]
Recognized revenue	$ 10,828	$ 68,139
Inventory net	4,071,824	1,239,725
[custom:AccountsPayableRelatedParties-0]		0
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Inventory net	12,747,006	1,505,390
PMI License Agreement [Member]
Related Party Transaction [Line Items]
[custom:NonrecurringEngineeringCostsPayable-0]	$ 712,524
Philip Morris [Member]
Related Party Transaction [Line Items]
[custom:LicenseFeesEquivalentPercentage]	50%
Nirajkumar Patel [Member]
Related Party Transaction [Line Items]
Recognized revenue	$ 10,828	68,139
Purchased Products equal	12,747,006	1,505,390
Accounts payable balance	$ 1,521,491	$ 0

Income Tax (Details)

Income Tax (Details) - USD ($)	12 Months Ended
Income Tax (Details) - USD ($)	Oct. 31, 2023	Oct. 31, 2022
Current Tax Expense:
Federal	$ 0	$ 0
State	2,348	(18,317)
Total Current Tax Expense	2,348	(18,317)
Deferred Tax Expense:
Federal	0	0
State	0	0
Total Deferred Tax Expense	0	0
Tax provision:
Federal	0	0
State	2,348	(18,317)
Total	$ 2,348	$ (18,317)

Income Tax (Details 1)

Income Tax (Details 1) - USD ($)	Oct. 31, 2023	Oct. 31, 2022
Deferred Tax Assets:
Stock Compensation Expense – NQSO	$ 2,069,641	$ 1,694,324
Other	499,203	362,170
Net Operating Loss Carryforwards	4,998,800	2,582,061
Total Deferred Tax Asset	7,567,644	4,638,555
Deferred Tax Liabilities:
Prepaid Expenses	(27,497)	(92,420)
Right of Use Asset	(220,859)	(259,866)
Total Deferred Tax Liabilities	(248,356)	(352,286)
Less: Valuation Allowance	(7,319,288)	(4,286,269)
Net Deferred Tax Asset	$ 0	$ 0

Income Tax (Details Narrative)

Income Tax (Details Narrative) - USD ($)	12 Months Ended
Income Tax (Details Narrative) - USD ($)	Oct. 31, 2023	Oct. 31, 2022
Operating Loss Carryforwards [Line Items]
U.S. federal and state income tax rate	35%	21%
Statutory corporate income tax rate	4.458%
Determined valuation allowance	$ 7,319,289	$ 4,286,289
Deferred Tax Asset [Member]
Operating Loss Carryforwards [Line Items]
Determined valuation allowance	$ 7,319,288

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

12 Months Ended

Aug. 02, 2022

Feb. 04, 2022

Dec. 02, 2021

Aug. 24, 2022

Jun. 30, 2022

Jun. 24, 2022

Apr. 24, 2022

Mar. 17, 2021

Apr. 30, 2022

Oct. 31, 2023

Oct. 31, 2022

Oct. 28, 2022

May 18, 2022

Sep. 30, 2021

Commitments and contingencies

$ 0

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period

1,985

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 602.28

$ 14.70

$ 39.90

Stock options expense

190,000

Vested term

10 years

Exercise price per share

$ 21.63

Accrued bonuses current

$ 50,000

$ 33,871

Settlement amount

$ 150,000

Bonus description

cash bonus award equal to $30,000 for every $25 million in
gross revenues generated by the Company. With respect to the Chief Operating Officer, the Board approved a cash bonus award equal to
$20,000 for every $25 million in gross revenues generated by the Company. On May 28, 2020, the Board also approved an equity bonus award
for each of the Chief Executive Officer and the Chief Operating Officer. With respect to the Chief Executive Officer, the Board approved
an award of 358 restricted shares of the Common Stock for every $50 million in accumulated gross revenues generated by the Company. With
respect to the Chief Operating Officer, the Board approved an award of 298 restricted shares of the Common Stock for every $50 million
in accumulated gross revenues generated by the Company.

Cash bonuses

$ 125,000,000

Purchase Price

$ 81,300

Nirajkumar Patel [Member]

Acquire shares

11,905

Exercisable price per share

$ 36.12

Eric Mosser [Member]

Acquire shares

11,905

Exercisable price per share

$ 36.12

Incentive Compensation Plan [Member]

Number of shares granted

1,191

Exercisable

$ 24.36

Consulting Agreement [Member]

Incentive compensation bonus

$ 75,000

Non qualified stock options exercisable

3,572

Number of shares granted

2,381

1,786

Exercisable

$ 27.72

$ 29.82

Inflection Partners [Member] | Consulting Agreement [Member]

Services description

Company entered into a Consulting
Agreement with Oakhill Europe Ltd (“Oakhill Europe”), pursuant to which the Company engaged Oakhill Europe to provide strategic
advising and negotiation assistance for potential international distribution agreements (collectively, the “Oakhill Services”),
in exchange for a $15,000 monthly retainer, incentive compensation bonuses of up to $175,000, and an incentive compensation bonus value
of $75,000 paid in fully-vested non-qualified stock options, upon the achievement of certain events

Common Stock [Member]

Stock options exercisable shares

23,810

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Dec. 02, 2023	Nov. 29, 2023	Dec. 15, 2023	Oct. 31, 2023
Subsequent Event [Line Items]
Principal amount				$ 134,176
Subsequent Event [Member]
Subsequent Event [Line Items]
Accrued interest	$ 650,181
Subsequent Event [Member] \| F I N R A [Member]
Subsequent Event [Line Items]
Number of shares issued			16,667
Subsequent Event [Member] \| Clearview Agreement [Member]
Subsequent Event [Line Items]
Principal amount		$ 864,000
Private transaction purchase price		600,000
Original issue discount		264,000
Underwriting cost		36,520
Net proceeds		563,480
Subsequent Event [Member] \| Advance Agreement [Member]
Subsequent Event [Line Items]
Principal amount		864,000
Private transaction purchase price		600,000
Original issue discount		264,000
Underwriting cost		36,035
Net proceeds		$ 563,965